

Journal Pre-proof

Saliva as a Matrix for Primary Care: Feasibility and Scoping of its Use for Assessment of Nutrition and Inflammation

Shah Mohammad Fahim, MBBS, Mahesa Miah, Mia Marcotte, Nancy Zoria, Mahdia Ahmed, Samantha L. Huey, PhD, David Erickson, PhD, Julia L. Finkelstein, ScD, Saurabh Mehta, MBBS, ScD

PII: S2161-8313(26)00039-6

DOI: <https://doi.org/10.1016/j.advnut.2026.100625>

Reference: ADVNUT 100625

To appear in: *Advances in Nutrition*

Received Date: 17 November 2025


Revised Date: 23 March 2026

Accepted Date: 27 March 2026

Please cite this article as: S.M. Fahim, M. Miah, M. Marcotte, N. Zoria, M. Ahmed, S.L. Huey, D. Erickson, J.L. Finkelstein, S. Mehta, Saliva as a Matrix for Primary Care: Feasibility and Scoping of its Use for Assessment of Nutrition and Inflammation, *Advances in Nutrition*, <https://doi.org/10.1016/j.advnut.2026.100625>.

This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability. This version will undergo additional copyediting, typesetting and review before it is published in its final form. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Please note that Elsevier's sharing policy for the Published Journal Article applies to this version, see: <https://www.elsevier.com/about/policies-and-standards/sharing#4-published-journal-article>. Please also note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Nutrition.



Saliva as a Matrix for Primary Care: Feasibility and Scoping of its Use for Assessment of Nutrition and Inflammation

Shah Mohammad Fahim, MBBS^{1,2}, Mahesa Miah², Mia Marcotte², Nancy Zoria², Mahdia Ahmed², Samantha L Huey, PhD^{1,2}, David Erickson, PhD^{3,4}, Julia L Finkelstein, ScD^{1,2,4,5}, Saurabh Mehta, MBBS, ScD^{1,2,4,5*}

¹ Cornell Joan Klein Jacobs Center for Precision Nutrition and Health, Cornell University, Ithaca, NY 14853, USA

² Division of Nutritional Sciences, Cornell University, Ithaca, NY 14853, USA

³ Sibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, NY 14853, USA

⁴ NIH Center for Point-of-Care Diagnostics for Nutrition, Infection, and Cancer for Global Health (PORTENT), Cornell University, Ithaca, NY 14853, USA

⁵ Division of Epidemiology, Department of Population Health Sciences, Cornell Weill Medicine, New York City, NY, USA

* Correspondence: Dr. Saurabh Mehta, The Janet and Gordon Lankton Professor and Founding Director, Cornell Joan Klein Jacobs Center for Precision Nutrition and Health, Cornell University, 3101 Martha Van Rensselaer Hall, 37 Forest Home Drive, Ithaca, NY 14853, USA, Phone: (607) 255-2640, Email: smehta@cornell.edu.

Sources of support: Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development under award number R21HD103974 and the National Institute of Biomedical Imaging and Bioengineering and Fogarty International Center of the National Institutes of Health under Award Number U54EB034654 - PORTENT: A Center for Point of Care Technologies for Nutrition, Infection, and Cancer. PORTENT is a member of the POCTRN+ Network. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Abbreviations:

AGP: alpha-1 acid glycoprotein; CMIA: chemiluminescence microparticle immunoassay; CP: chronic periodontitis; CRP: C-reactive protein; DBP: vitamin D binding protein; DPP-4: dipeptidyl peptidase-4; ELISA: enzyme-linked immunosorbent assay; IgA: Immunoglobulin A; IgG: Immunoglobulin G; IRMA: immunoradiometric assay; LOD: limit of detection; OL: oral leukoplakia; OLP: oral lichen planus; OSCC: oral squamous cell carcinoma; OSMF: oral submucous fibrosis; PD: periodontitis; PRISMA: preferred reporting items for systematic reviews and meta-analyses; RA: rheumatoid arthritis; RBP: retinol-binding protein; RCT: randomized controlled trial; sTfR: soluble transferrin receptor; T2DM: type 2 diabetes mellitus; WRA: women of reproductive age.

Abstract

1 Scarce laboratory capacity constrains both primary care and population surveillance for nutritional
2 and inflammation assessment globally. One major contributing factor is the reliance on blood as
3 the primary matrix, and its associated limitations of being invasive, having relatively lower
4 acceptance in apparently healthy individuals and community settings, and being heavily dependent
5 on laboratory and related infrastructure. Saliva offers a non-invasive, inexpensive, and more
6 convenient alternative that causes less discomfort and has the potential to expand the portfolio of
7 point-of-care testing for nutrition and inflammation assessment in primary care. We aimed to
8 synthesize the evidence on the feasibility and scope of using salivary biomarkers for nutrition and
9 inflammation assessment. A literature search was conducted in MEDLINE and CINAHL, without
10 restrictions on language, geographic location, or publication date. Screening and data extraction
11 were done in duplicate on Covidence. A narrative synthesis was done to summarize the results.
12 Seventy-six studies examining salivary biomarkers for nutrition and inflammation were identified
13 across 26 countries, involving 5425 children and 5617 adults. We summarized the results from 33
14 studies assessing ferritin, iron, zinc, calcium, vitamin A, vitamin B12, vitamin D, vitamin C, and
15 vitamin E in saliva. Additionally, we found 43 studies evaluating salivary inflammatory
16 biomarkers, including C-reactive protein, alpha-1 acid glycoprotein, hepcidin, immunoglobulin A,
17 and cytokines within the context of nutritional impairments. While most biomarker values were
18 detectable in saliva, significant evidence and methodological gaps remain, including the absence
19 of standardized protocols for sample collection, transportation, processing, storage, and laboratory
20 analysis; insufficient information on diagnostic performance, accuracy, and comparability with
21 corresponding blood biomarkers; and challenges in interpreting findings across different
22 population subsets and settings. Future research should focus on improving method reporting and
23 ensuring the clinical relevance of findings to maximize the potential of saliva-based diagnostics
24 for nutrition and inflammation assessment.

25 **Keywords:** Saliva; Biomarkers; Nutritional Status; Nutrition Assessment; Cytokines; Point-of-
26 Care.

27 **Statement of Significance:** This review synthesizes the current evidence on the feasibility and
28 scope of using salivary biomarkers for nutrition and inflammation assessment. We also identify

29 research gaps and methodological challenges for the use of saliva as a matrix for primary care, as
30 well as in nutrition and biomedical research.

Journal Pre-proof

31 **Introduction**

32 Scarce laboratory capacity constrains both primary care and population surveillance for nutritional
33 and inflammation assessment globally (1, 2). One major contributing factor is the reliance on
34 whole blood or serum as the primary body fluid for assessing nutritional and inflammatory
35 biomarkers, and its associated limitations of being invasive, having relatively lower acceptance in
36 apparently healthy individuals and community settings, and being heavily dependent on laboratory
37 and related infrastructure (3). While blood is considered the standard body fluid to assess most
38 biomarkers, saliva may be a preferable alternative in terms of sample collection (4, 5). Compared
39 to blood, collecting saliva is non-invasive, cheaper to collect and process, and more convenient to
40 collect from anyone in any setting (6, 7). Saliva is an extracellular fluid produced and secreted by
41 major and minor salivary glands (8), containing various biocomponents and metabolites that help
42 maintain oral cavity health (9). Sufficient saliva is necessary to uphold a neutral pH in the oral
43 cavity, protect oral tissues from microorganisms, and assist with swallowing and digestion (10,
44 11). In children, saliva plays a pivotal role in oral health, contributing to antimicrobial defense and
45 enamel remineralization, while in adults, it supports oral homeostasis, digestion, and immune
46 function, with variations in composition influenced by age, medication use, and systemic health
47 conditions (12). Saliva also plays a crucial role in taste perception and the maintenance of oral
48 hygiene (13). Saliva consists of secretions from both major and minor salivary glands, along with
49 components from the upper respiratory tract and the gingival crevicular fluid (14). Although 99%
50 of saliva is water, the biological composition of salivary fluid is almost similar to that of blood (6,
51 15). Proteins and other components found in serum also enter saliva from the blood through passive
52 diffusion, active transport, or ultrafiltration (16). Recent evidence on salivary proteomes revealed
53 similarities between salivary proteins and the plasma proteomes (17). Saliva contains various

54 substances, including electrolytes, enzymes, mucus, and antibodies (13). Additionally, a variety of
55 macro and trace elements, such as inorganic ions, proteins, hormones, and immunological
56 components essential for oral and systemic health, were detected in saliva, and these components
57 can regulate the immune-inflammatory pathways and are involved in the maintenance of oral
58 health homeostasis (18). Several nutritional, inflammatory, and immune response molecules are
59 also abundant in the saliva (19). Advantages of saliva collection also include reduced risk of
60 infectious disease transmission, ease of multiple sampling, and higher acceptance by patients and
61 caregivers (9, 20). However, salivary volume and composition may differ among individuals based
62 on several biological factors, including age, sex, mood, stress, nervous system activity, circadian
63 rhythms, disease status, oral health conditions, and salivary flow rate (21). Salivary biomarker
64 concentrations are also influenced by diet, hydration status, and the time of sample collection (21).
65 Moreover, the lack of standardization in the collection, processing, storage, and laboratory analysis
66 of saliva samples, along with persistent gaps in the diagnostic utility and interpretability of salivary
67 biomarkers, limits their reliability in clinical and research settings (13).

68 Despite the limitations, salivary analytes hold promise for use as a matrix for primary care for the
69 assessment of health and diseases, particularly in low-resource settings or hard-to-reach remote
70 areas. They offer the potential to evaluate both oral and systemic conditions. In dentistry and
71 periodontology, biomarkers such as matrix metalloproteinases and interleukins can assess gingival
72 inflammation (22) and periodontal disease progression (23), respectively. Some other salivary
73 biomarkers, including various proteins and cytokines, have been found to be elevated in
74 individuals with dental caries, periodontitis, and gingivitis (14, 22, 24). Salivary biomarkers have
75 been used in infectious diseases, for example, for reliably detecting SARS-CoV-2 (via the
76 antibodies to the SARS-CoV-2 spike glycoprotein) in individuals exposed to COVID-19 (25).

77 Saliva may also be a key indicator of inflammation, as it contains cytokines and other inflammatory
78 mediators that reflect immune responses in conditions such as dental caries, periodontal diseases,
79 and systemic infections (26-28). Studies have also confirmed the use of salivary biomarkers in
80 endocrine disorders (for example, salivary cortisol to identify patients with Cushing's syndrome
81 and Addison's disease), autoimmune diseases (for example, increased concentrations of
82 immunoglobulin A (IgA), immunoglobulin G (IgG), lactoferrin, and albumin, and a decreased
83 level of phosphate in saliva of patients with Sjögren Syndrome), and malignancy (for example,
84 p53 antibody and various cytokines in saliva for early detection and screening of oral squamous
85 cell carcinoma (14, 29, 30). Salivary analytes reflecting nutritional and inflammatory status have
86 been reported across various studies. Inflammation can be assessed in saliva by measuring various
87 cytokines and CRP. Certain immune function biomarkers, such as IgA, are also found in saliva
88 (31). Several nutritional biomarkers can also be quantified in saliva. However, the concentration
89 of these biomarkers, relative to their counterparts in blood, remains understudied. Transferrin and
90 iron are generally at lower concentrations in saliva compared to blood, while zinc and IgA have
91 been found at higher levels (31, 32). Although salivary biomarkers have already been used in some
92 healthcare contexts, their widespread adoption as a matrix for nutrition and inflammation
93 assessment is constrained by the lack of established guidelines (33). Furthermore, evidence on the
94 feasibility and use of salivary biomarkers for nutrition and inflammation assessment is limited,
95 particularly in the context of primary care. This article aims to review the feasibility and scope of
96 using salivary biomarkers for assessing nutrition and inflammation, as well as evaluating
97 nutritional disorders. Additionally, we identify research gaps and suggest priority areas for future
98 investigation in the context of primary care facilities.

99 **Methods**

100 The research question and search strategy were developed in July 2024. A comprehensive
101 literature search was conducted thereafter in MEDLINE (PubMed) and CINAHL (Ebsco), with no
102 restrictions on language, geographic location, or date of publication. The search strategy was
103 specifically developed for MEDLINE and is detailed in Supplementary File 2. This search strategy
104 was translated and refined for CINAHL with assistance from evidence synthesis specialists at the
105 Mann Library, Cornell University. We also used an online search engine to search for other
106 sources, such as manufacturers' websites, to gain more information. The workflow for inclusion
107 of the studies in the review is outlined in Supplementary File 1.

108 The review included pilot studies, observational studies, randomized controlled trials (RCTs), and
109 quasi-RCTs that met all predefined inclusion criteria. Ecological studies, narrative reviews,
110 systematic reviews, commentaries, letters, expert opinions, book chapters, short communications,
111 and animal studies were excluded. Eligible studies were conducted in diverse settings, including
112 hospitals, healthcare facilities, and community environments, to maximize the inclusion of
113 relevant research. The inclusion criteria for studies were as follows: diagnostic and screening
114 studies utilizing salivary biomarkers for the assessment of nutritional disorders and inflammation,
115 and studies involving cases of malnutrition, nutrient deficiencies, nutrition-related metabolic
116 disorders, and inflammatory conditions.

117 Participants of any age or sex, with any health condition or lack thereof, were included if their
118 saliva samples were used to measure biomarkers for nutrition or inflammation. Health conditions
119 considered for inclusion encompass malnutrition (both undernutrition and overnutrition), nutrient
120 deficiencies (e.g., vitamin and mineral deficiencies), nutrition-related metabolic disorders, and
121 inflammatory conditions. Studies involving participants with health conditions unrelated to
122 nutritional problems or inflammation (e.g., acute kidney injury, autoimmune liver disease,

123 squamous cell carcinoma) were excluded. No intervention was required for study inclusion. The
124 primary outcome was the examination of salivary biomarkers for assessing nutritional status and
125 inflammation, as well as the evaluation of nutritional disorders. The secondary outcome involved
126 the profiling and quantification of salivary biomarkers associated with nutritional disorders and
127 inflammatory conditions. Studies were excluded if none of the relevant outcomes were measured,
128 or if they provided no supporting evidence (e.g., contact with authors or access to the original
129 protocol). Table 1 shows the number of articles for each biomarker.

130 Two review authors independently screened titles and abstracts to identify studies for full-text
131 assessment. Subsequently, full texts were screened by the same two authors. Any disagreements
132 during screening were resolved by consensus or through consultation with a third author.
133 Covidence software was used to facilitate the screening process. The selection process, including
134 the total number of included studies, is illustrated in the PRISMA flowchart (Figure 1) (34). Key
135 information from the included studies was extracted independently by two review authors.
136 Disagreements during data extraction were resolved through discussion or, if necessary, by
137 consulting a third review author. This rigorous process ensured consistency and accuracy in the
138 data collected for the review.

139 *Statistical analysis*

140 We performed random-effects meta-analysis using the “metafor” package in R to estimate the
141 pooled correlation between serum and salivary biomarkers, including ferritin, iron, vitamin D,
142 and C-reactive protein (CRP). Spearman correlation coefficients were converted to Pearson
143 correlation coefficients using established transformation methods before inclusion in the meta-
144 analysis. Correlation coefficients were then transformed to Fisher’s z values to stabilize
145 variances and normalize their distribution. Pooled estimates were calculated on the Fisher’s z

146 scale and subsequently back-transformed to Pearson's r for interpretation. We reported the
147 pooled correlation coefficients (r) with 95% confidence interval (CI), along with measures of
148 heterogeneity (i.e., I^2 and τ^2). All statistical analyses were performed in R version 4.5.2.

149 **Results**

150 **1. Saliva biomarkers for nutrition assessment**

151 **a. Ferritin**

152 Iron is an essential mineral crucial for various biological functions in the body, including oxygen
153 transport, blood cell production, amino acid synthesis, energy production, and immune cell
154 regulation (35). Iron deficiency impairs immune function and increases susceptibility to infections
155 (36). It is also necessary for the optimal growth and development of the immune system. Most iron
156 is found in the erythroid bone marrow and mature erythrocytes, within the heme moiety of
157 hemoglobin. The iron needed for red blood cell synthesis (erythropoiesis) is mainly supplied by
158 reticuloendothelial macrophages, which recycle iron from old red blood cells. Stored iron bound
159 to ferritin is primarily found in the hepatocytes (35). Circulating iron is bound to transferrin, which
160 accounts for about 0.1% of total body iron in transit compartments. Transferrin delivers iron to
161 developing erythroid precursors and other tissues (35). Iron distribution changes in response to
162 pregnancy, iron deficiency, and iron overload (35). Biomarkers such as serum ferritin (SF), soluble
163 transferrin receptor (sTfR), and total body iron are used to evaluate iron status. Ferritin was
164 identified in saliva almost four decades ago (37) and has been evaluated in various studies (38-
165 40). Earlier work suggests that changes in salivary ferritin occur even before the hematological
166 ferritin changes (41). Ferritin is highly conserved in saliva, perhaps due to the iron-binding
167 capacity of saliva and the iron-dependent enzymatic functions of the saliva (41). However, the
168 specific biochemical mechanism underlying this conservation and iron homeostasis in the salivary

169 matrix is unclear. Moreover, research on salivary iron biomarkers in the context of nutrition and
170 inflammation assessment is limited.

171 We identified seven studies that assessed salivary ferritin concentrations (42-48). The findings
172 regarding salivary ferritin suggest its potential role as a noninvasive biomarker for assessing iron
173 status. The discrepancy in salivary ferritin levels between the studies may be explained by
174 differences in sample size, age of patients, and individual health status. The sample collection,
175 processing, storage, laboratory analysis methods, and instruments used for quantifying salivary
176 ferritin concentrations are reported in Supplementary File 3. The summary of studies with salivary
177 ferritin and results are shown in Table 2 and Supplementary File 4. Two studies reported higher
178 salivary ferritin concentrations than serum ferritin levels, whereas three studies reported higher
179 serum ferritin concentrations than salivary ferritin. Two studies did not report serum ferritin
180 concentrations. Only four studies examined the correlation between serum and salivary ferritin
181 levels (42, 44-46). A random-effects meta-analysis of these four studies demonstrated a moderate
182 positive pooled correlation of 0.47 (95% CI: 0.21 to 0.67) (Figure 2). Although the heterogeneity
183 was substantial ($I^2 = 87.7\%$, $\tau^2 = 0.08$), the direction of association was consistently positive,
184 supporting an overall positive relationship between serum and salivary ferritin concentrations.
185 Overall, the findings suggest that salivary ferritin holds promise as a noninvasive biomarker;
186 however, its clinical utility is limited by inter-study discrepancies likely arising from differences
187 in the sample collection and processing protocols, assay methods, population heterogeneity, oral
188 health status, and underlying disease conditions.

189 **b. Iron (Fe)**

190 We identified five studies that assessed salivary iron (Fe) levels (18, 42, 44, 49, 50). The sample
191 collection, processing, storage, laboratory analysis methods, and instruments used for quantifying
192 salivary iron (Fe) concentrations are reported in Supplementary File 3.

193 The summary of the results of salivary iron is highlighted in Table 3 and Supplementary File 4.

194 All five studies detected Fe in saliva samples, but the levels varied across studies and among
195 different study populations. Two studies reported lower salivary ferritin concentrations than serum
196 ferritin levels, whereas only one study reported higher salivary ferritin concentrations than serum
197 ferritin (Table 3). Two studies reported the correlations between serum and salivary levels of Fe.
198 A meta-analysis of these two studies using a random-effects model showed a positive pooled
199 correlation of 0.76 (95% CI: -0.12 to 0.97) (Figure 2). Heterogeneity was substantial ($I^2 = 97.7\%$,
200 $\tau^2 = 0.649$), indicating considerable variability in effect sizes across studies. Despite this
201 heterogeneity, each study reported a positive correlation, supporting a consistent positive
202 relationship between serum and salivary Fe levels.

203 **c. Soluble Transferrin Receptor (sTfR)**

204 No studies evaluating sTfR in saliva met our inclusion criteria.

205 **d. Zinc**

206 Zinc is an essential trace element that plays a vital role in maintaining various metabolic functions
207 in the human body (51). Zinc deficiency is associated with impaired metabolism, growth
208 retardation, and an increased risk of infectious diseases (52). This micronutrient is particularly
209 critical for young children, as inadequate zinc levels are linked to stunting, wasting, and increased
210 morbidity and mortality during the early years of life. Zinc plays a key role in physical growth,
211 neurobehavioral development, and reproductive health (51). Additionally, zinc supplementation is
212 effective in managing acute and persistent diarrheal diseases, with evidence suggesting that zinc

213 supplementation can reduce the duration of acute diarrhea in children. Plasma or serum zinc
214 concentration is commonly used as a biomarker for assessing zinc status (52). However, it is
215 influenced by multiple biological factors, including age, sex, dietary intake, stress, pregnancy, and
216 circadian variations (51). Additionally, plasma or serum zinc levels are tightly regulated through
217 homeostatic mechanisms and typically reflect only a small fraction of total body zinc (53). Thus,
218 severe zinc deficiency is required to elicit measurable changes in plasma or serum zinc
219 concentrations. Moreover, plasma zinc levels do not reliably reflect short-term exposure to zinc
220 supplements or zinc-fortified foods and exhibit significant variability across different populations
221 (51). Therefore, in addition to plasma or serum zinc levels, dietary zinc intake and height-for-age
222 z-scores (or stunting status) are recommended for a more comprehensive assessment of zinc status
223 (51, 52).

224 Research on salivary zinc as a biomarker remains limited. Some studies suggest that hypogeusia
225 (diminished taste acuity) is a characteristic of zinc deficiency and could serve as a functional
226 indicator of zinc status (51). Consequently, salivary zinc measurement may offer an alternative
227 approach for assessing zinc deficiency, though further investigation is needed to validate its
228 reliability. We identified seven studies that assessed salivary zinc concentrations (49, 54-59). The
229 sample collection, processing, storage, laboratory analysis methods, and instruments used to
230 quantify salivary zinc concentrations are reported in Supplementary File 3. The substantial
231 heterogeneity in sampling protocols and salivary zinc quantification methods across the seven
232 studies assessing salivary zinc concentrations raises concerns regarding the comparability and
233 methodological reliability of their reported findings. The summary of the results is highlighted in
234 Supplementary File 4. The salivary levels of zinc were lower than the serum zinc levels in two
235 studies (54, 55). In one study, salivary zinc concentrations were undetectable for a significant

236 proportion of the participants (55). Only one study examined the correlations between salivary and
237 plasma zinc concentrations, but it didn't observe a significant relationship (56). These findings
238 indicate that the current evidence regarding salivary zinc is insufficient and inconsistent across
239 populations and study settings, limiting our ability to justify the use of salivary zinc as a reliable
240 alternative. Further research is required to assess its diagnostic performance and to define
241 population-specific reference ranges and cutoff values.

242 **e. Calcium**

243 Calcium is essential for bone growth. Salivary calcium secretions are typically oversaturated,
244 which helps the formation of dental enamel and plays an important role in the protection of teeth
245 (60). Salivary levels of calcium increase physiologically when the salivary flow rate decreases
246 (61). This may not be true for patients with anemia, for whom the salivary calcium level can be
247 lower due to impaired absorption in the gastrointestinal tract. The evidence on salivary calcium
248 concentration is currently limited. Previous work suggests that elevated salivary calcium levels
249 may be associated with reduced bone mineral density and could serve as a functional marker of
250 bone health, particularly in postmenopausal women (62). Therefore, measuring salivary calcium
251 may offer a non-invasive alternative for evaluating calcium deficiency and bone health conditions
252 (12). However, further research is necessary to confirm its accuracy and clinical utility.

253 In this review, we identified six studies that assessed salivary calcium levels (63-68). The sample
254 collection, processing, storage, laboratory analysis methods, and instruments used for calcium
255 quantification are reported in Supplementary File 3. All six studies investigating salivary calcium
256 levels were cross-sectional in design. A summary of their findings is presented in Supplementary
257 File 4. Salivary calcium levels were detected in all six studies, with reported concentrations
258 ranging from 0.062 mg/dL to 18.79 mg/dL. None of the studies measured calcium levels in blood.

259 Two studies found significantly lower salivary calcium levels in participants with different
260 nutritional impairments (e.g., patients with Fanconi anemia and children with moderate to severe
261 protein-energy malnutrition) compared to the controls (64, 68). On the other hand, one study
262 reported no significant differences in salivary calcium levels between the children with normal
263 weight, overweight, and obesity (63). One study observed a significantly positive correlation
264 between salivary calcium levels and serum concentrations of vitamin D (66). Another study
265 reported a statistically significant negative correlation between bone mineral density and salivary
266 calcium levels (65). These findings suggest that salivary calcium levels vary across different
267 populations and clinical contexts.

268 **f. Vitamin A**

269 Vitamin A is an essential micronutrient that can be obtained from both plant and animal sources
270 (69). The form found in plants is provitamin A carotenoid, while the form found in animal sources
271 is retinol (70). Vitamin A plays a crucial role in vision, cellular growth, differentiation, and
272 maintaining immune functions (70). Vitamin A deficiency is a global concern, particularly
273 affecting children in low-income settings (71). This deficiency can cause night blindness,
274 xerophthalmia, and an increased risk of infectious diseases, especially in young children (69).
275 Vitamin A is absorbed and stored in the liver as retinol and is released into circulation bound to
276 retinol-binding protein (RBP). Serum or plasma retinol is the most used biomarker for assessing
277 vitamin A status, and serum RBP is used as a proxy for serum retinol in identifying vitamin A
278 deficiency (69). However, there are significant challenges in sample collection and transportation
279 for the assessment of these biomarkers (69). The most accurate tests for vitamin A, including serum
280 or plasma retinol and retinol-binding protein, are invasive, costly, time-consuming, and technically

281 demanding. Therefore, saliva can be an alternative biofluid for the assessment of vitamin A status
282 (72).

283 We identified two studies evaluating salivary vitamin A status. The sample collection, processing,
284 storage, laboratory analysis methods, and instruments used to quantify salivary vitamin A
285 concentrations in these studies are reported in Supplementary File 3. Table 4 and Supplementary
286 File 4 summarize the findings from studies that assessed salivary vitamin A. One study reported
287 significantly higher salivary vitamin A levels in males than females ($P = 0.003$) (72). Although the
288 exact biological reason for this difference is unknown, it can be due to hormonal influences, larger
289 salivary gland size, or differences in salivary flow rate between male and female participants.
290 Another study assessed salivary retinol-binding protein (RBP) in healthy individuals (73). The
291 findings suggest that RBP is secreted by all major salivary glands. They observed a higher salivary
292 RBP concentration in resting samples compared to that in stimulated samples; however, it was not
293 statistically significant. Conversely, the salivary output of RBP was significantly higher in
294 stimulated samples compared to resting samples ($p < 0.05$), suggesting an increased secretion rate
295 upon stimulation. In this study, salivary RBP concentrations did not demonstrate significant linear
296 relationships with serum RBP or serum retinol levels (73).

297 **g. Vitamin D**

298 Vitamin D, a fat-soluble vitamin, is essential for calcium absorption and bone formation in children
299 (74). The insufficiency or deficiency of vitamin D is a common problem in the general population
300 (75). Vitamin D deficiency causes hypocalcemia, rickets, and osteomalacia in children and adults.
301 Additionally, the deficiency of vitamin D was found to be associated with obesity, insulin
302 resistance, diabetes mellitus, and cardiovascular diseases (75, 76). Vitamin D is commonly
303 assessed in blood, and the widely accepted biomarker is 25-hydroxyvitamin D (25(OH)D) (77).

304 However, the optimal level of this biomarker is debated, and there are ongoing challenges in
305 standardizing assay methods for measuring 25-hydroxyvitamin D (25(OH)D) in blood samples
306 (78).

307 Research on the assessment of vitamin D biomarkers in saliva is still limited. We identified nine
308 studies evaluating salivary vitamin D status (72, 73, 79-85). All but one study assessed either
309 vitamin D2 or D3 in saliva. The methods for sample collection, processing, storage, laboratory
310 analysis, and instruments used for quantifying salivary vitamin D concentrations are reported in
311 Supplementary File 3. The summary of the results is highlighted in Table 5 and Supplementary
312 File 4. Only four studies assessed serum concentrations of vitamin D, and three studies investigated
313 the correlations between serum and salivary levels of vitamin D. A random-effects meta-analysis
314 of these three studies showed a moderate positive pooled correlation ($r = 0.51$, 95% CI: 0.11 to
315 0.77) between serum and salivary vitamin D levels (Figure 2). Heterogeneity was substantial ($I^2 =$
316 90.9%, $\tau^2 = 0.15$), indicating considerable variability in effect sizes across studies. Despite this
317 heterogeneity, all studies reported positive correlations, supporting an overall positive relationship
318 between serum and salivary vitamin D. Only one study assessed salivary levels of vitamin D-
319 binding protein (DBP) and observed a significant positive correlation between serum and salivary
320 levels of DBP (73). Two studies found that salivary vitamin D levels were lower than serum levels
321 in both healthy controls and in patients with different oral health conditions (Table 5). One study
322 observed statistically significant negative correlations between salivary vitamin D and BMI Z-
323 score, body fat percentage, waist circumference, and weight-to-height ratio (83). However, another
324 study reported no statistically significant differences in salivary vitamin D2 or vitamin D3 levels
325 between the adolescents divided into groups based on their body fat percentage (82). The study

326 findings underscore the substantial heterogeneity among studies evaluating salivary vitamin D
327 levels and the inconsistencies observed across different population subsets.

328 **h. Vitamin B12**

329 Vitamin B12, also known as cobalamin, is an essential nutrient for humans (86, 87). This water-
330 soluble vitamin helps the formation of red blood cells, the production of DNA, and nerve function
331 in the body (87). The deficiency of vitamin B12 leads to pernicious anemia (87). After
332 consumption, vitamin B12 is transported to the small intestine by binding with salivary
333 haptocorrin, also known as R-binder (86). In the small intestine, the high pH causes haptocorrin to
334 release Vitamin B12, which is then absorbed in the terminal ileum (86). After absorption, the body
335 stores Vitamin B12 in the liver. Transport of B12 in the plasma is facilitated by two proteins:
336 haptocorrin and transcobalamin. Haptocorrin forms are found in various body fluids, including
337 plasma, saliva, bile, gastric juice, and breast milk (87). Transcobalamin is responsible for
338 delivering B12 to all tissues. Genetic deficiency of transcobalamin is associated with severe B12
339 deficiency, whereas genetic deficiency of haptocorrin appears to have little or no effect on
340 functional B12 status (86). Common biomarkers for Vitamin B12 assessment include serum (or
341 plasma) B12 concentration, serum holo-transcobalamin (holoTC) concentration, serum
342 methylmalonic acid (MMA) concentration, and plasma total homocysteine (tHcy) concentration
343 (86). Each of these biomarkers has limitations. For example, measuring serum (or plasma) vitamin
344 B12 concentrations is not feasible in the field, and samples must be protected from light during
345 collection and handling (86).

346 Saliva has potential as a biofluid for assessing Vitamin B12 status, but current evidence is very
347 limited regarding the assessment and validation of salivary biomarkers for vitamin B12 status. We
348 identified one study on salivary haptocorrin and three studies evaluating vitamin B12 levels in

349 saliva samples (44, 72, 73, 88). The sample collection, processing, storage, laboratory analysis
350 methods, and instruments used for quantifying salivary vitamin B12 concentrations are reported
351 in Supplementary File 3. We observed considerable variation across the included studies in terms
352 of sample collection, processing, storage, laboratory analysis, and the instruments used to quantify
353 salivary vitamin B12. Because of this heterogeneity, it was not possible to determine the most
354 reliable methods for collecting and processing saliva samples for vitamin B12 assessment.

355 Table 6 and Supplementary File 4 summarize the findings of the studies that assessed vitamin B12
356 in saliva. One study observed a significantly higher concentration of salivary haptocorrin in resting
357 samples compared to the chew-stimulated samples (73). This finding suggests an increased
358 secretion rate of salivary haptocorrin upon stimulation. They also observed a moderate correlation
359 between salivary haptocorrin in stimulated and resting samples ($r = 0.57$). In this study, salivary
360 haptocorrin concentrations were not associated with serum haptocorrin ($r^2 = 0.02$, $p > 0.05$) or
361 serum total vitamin B12 levels ($r^2 = 0.08$, $p = 0.05$) (73). One study reported higher salivary
362 vitamin B12 concentrations than serum vitamin B12 levels, whereas another study reported higher
363 serum vitamin B12 concentrations than salivary vitamin B12 (Table 6). Only one study reported
364 the correlation between serum and salivary levels of vitamin B12; however, the strength of
365 correlation was very poor ($r = 0.16$, $p\text{-value} = 0.035$) (44).

366 **i. Folic acid or Folate**

367 Folic acid, also known as folate, is a B vitamin crucial for healthy cellular growth and
368 development, particularly important during early pregnancy to prevent neural tube defects in the
369 newborn baby (89). Serum folate, red blood cell (RBC) folate, and plasma homocysteine
370 concentrations are commonly used as biomarkers of folate status (89). There is limited evidence
371 regarding the levels of folic acid in the saliva. We identified only one study evaluating salivary

372 folic acid or folate (44). In this study, salivary folic acid concentrations were detected higher than
373 the measurable upper limit of detection (i.e., >24 ng/mL) (44).

374 **j. Vitamin C**

375 We identified only two studies that assessed salivary vitamin C concentrations (72, 90). The
376 sample collection, processing, storage, laboratory analysis methods, and instruments used for
377 quantifying salivary vitamin C concentrations are reported in Supplementary File 3. The summary
378 of the findings is reported in Supplementary File 4. An intervention study showed a significant
379 increase in both serum and salivary vitamin C levels one week after curcumin intake and at the
380 end of the study across all groups. Salivary vitamin C levels were much lower than the serum
381 levels of vitamin C across all groups at all time points. They also observed a strong positive
382 correlation between serum and salivary vitamin C levels across all study groups (90). Another
383 study reported a significantly higher concentration of salivary vitamin C levels among patients
384 with non-erosive Lichen Planus compared to the patients with erosive Lichen Planus (72). They
385 didn't examine the correlation between serum and salivary levels of vitamin C.

386 **k. Vitamin E**

387 We identified only two studies that assessed salivary vitamin E concentrations (72, 90). The
388 methods of saliva collection, processing, storage, laboratory analysis, and instruments used for
389 quantifying salivary vitamin E concentrations are reported in Supplementary File 3. The summary
390 of the findings is reported in Supplementary File 4. An intervention study showed a significant
391 increase ($p < 0.05$) in both serum and salivary vitamin E levels one week after curcumin intake and
392 at the end of the study across all groups. The salivary vitamin E levels were much lower compared
393 to the serum levels of vitamin E across all groups at all time points. They observed a strong positive
394 correlation between serum and salivary vitamin C levels across all study groups (90). Another

395 study observed that salivary vitamin E levels were significantly higher among patients with non-
396 erosive Lichen Planus compared to the patients with erosive Lichen Planus. They didn't examine
397 the correlation between serum and salivary levels of vitamin C (72).

398 2. Saliva biomarkers for inflammation assessment

399 a. C-reactive protein (CRP)

400 C-reactive protein (CRP) is a positive acute-phase protein produced in the liver in response to
401 inflammation (91). CRP is released into the bloodstream when microbial invasion occurs and rises
402 quickly within the first 6 hours of infection onset (91). Changes in micronutrient levels during
403 infection and inflammation can mask the accurate assessment of certain micronutrients, including
404 iron and vitamin A biomarkers(92). Therefore, CRP is used as a marker of inflammation or
405 infection to help interpret micronutrient biomarkers (92, 93). An elevated level of CRP has also
406 been found to be associated with cardiometabolic risk factors and chronic diseases (94). CRP is
407 commonly assessed in blood samples; however, recent evidence showed the utility of salivary CRP
408 as a non-invasive alternative method for the assessment of inflammatory conditions. We identified
409 nine studies that measured salivary CRP levels (3, 95-102). The methods of saliva collection,
410 processing, storage, laboratory analysis, and instruments used for quantifying salivary CRP
411 concentrations are reported in Supplementary File 3. The summary of the results is highlighted in
412 Table 7 and Supplementary File 5. Three studies reported elevated levels of salivary CRP among
413 individuals with obesity. One study showed that overweight or obesity is an independent predictor
414 of elevated secretion rate of salivary CRP. Another study found that salivary levels of CRP were
415 positively correlated with BMI Z-score, waist circumference Z-score, and waist-to-height ratio Z-
416 score. The ROC curve analysis showed that salivary CRP has a promising diagnostic value to
417 determine obesity in children (97). Similarly, Tvarijonaviciute et al. 2019 observed a statistically

418 significant positive correlation between salivary CRP and BMI of the participants (3). However,
419 Wetterö et al. 2021 reported that no significant correlations were observed between BMI and
420 morning and evening values of CRP (98). Two studies didn't report any association of salivary
421 CRP with the BMI of the participants (99, 101). Only three studies examined the correlations
422 between serum and salivary levels of CRP levels (Table 7). The meta-analysis demonstrated a
423 moderate positive pooled correlation (Figure 2). Using a random-effects model, the combined
424 Fisher's z-transformed effect corresponded to a pooled correlation of 0.63 (95% CI: 0.29 to 0.83).
425 Heterogeneity was substantial ($I^2 = 96\%$, $\tau^2 = 0.149$), indicating considerable variability in effect
426 sizes across studies. Despite this heterogeneity, all studies reported positive correlations,
427 supporting an overall positive relationship between serum and salivary CRP. These findings
428 suggest that salivary CRP may serve as a promising, noninvasive biomarker for nutrition and
429 inflammation assessment. However, the current evidence remains limited and is weakened by
430 substantial heterogeneity in study design, sample characteristics, and analytical methods.

431 **b. Alpha-1 acid glycoprotein (AGP)**

432 AGP is a positive acute-phase protein whose serum concentration increases in response to infection
433 and inflammatory stimuli (103, 104). Elevated AGP levels have been associated with a wide range
434 of pathological conditions, including infections, tissue injuries, malignancies, cardiovascular
435 diseases, stroke, sepsis, obesity, diabetes, and metabolic syndrome (105). Unlike C-reactive
436 protein (CRP), which exhibits a rapid rise and decline during acute inflammation, AGP increases
437 more gradually and remains elevated for a prolonged period (105). This temporal difference allows
438 AGP and CRP to be used in combination to assess the phase and severity of inflammation, with
439 AGP being particularly relevant as a marker of chronic or prolonged inflammatory states (105).
440 AGP is routinely measured alongside CRP to interpret the time course and intensity of infections

441 that influence biomarkers of micronutrient status (104). Given its role in inflammation, it is
442 recommended that AGP be measured concurrently with CRP when evaluating and adjusting
443 micronutrient biomarkers, such as serum ferritin, sTfR, serum retinol, RBP, and serum zinc,
444 particularly in research and population-based nutritional surveys (104). While AGP is
445 predominantly assessed in serum samples, its application in noninvasive biofluids, such as saliva,
446 remains largely unexplored. We identified only one study that investigated salivary AGP,
447 highlighting a significant gap in the literature regarding its potential utility in nutrition and
448 inflammation research (105). Salivary alpha-1-acid glycoprotein (AGP) concentrations, as
449 measured by ELISA, exhibited a median (Q1, Q3) of 0.48 (0.41, 0.69) ng/mL, with a range of
450 0.27–3.64 ng/mL (105). They didn't examine the correlations between serum and salivary levels
451 of AGP.

452 **c. Hepcidin**

453 Hepcidin is a peptide hormone that is crucial in regulating iron homeostasis (106, 107). It is
454 primarily synthesized in the liver and released into circulation by binding to ferroportin, the main
455 iron-exporting protein (107). In response to elevated serum iron levels, hepcidin decreases dietary
456 iron absorption in the intestine and limits iron release from physiological stores (106). Conversely,
457 during conditions of iron deficiency, hepcidin production diminishes, facilitating increased iron
458 absorption and mobilization from storage sites to meet the body's needs (107). Clinical research
459 on hepcidin has largely focused on its involvement in iron-related disorders, including anemia of
460 chronic disease, hereditary hemochromatosis, and iron-loading anemias (106). Hepcidin has been
461 detected in various biological fluids such as serum, urine, saliva, bile, ascitic fluid, and pleural
462 fluid (108, 109). However, the precise concentration, regulatory mechanisms, and physiological
463 significance of hepcidin in these fluids remain incompletely understood, as data on its distribution

464 and function across different biological compartments are still limited. We identified two studies
465 that assessed salivary hepcidin concentrations (45, 108). The methods of saliva collection,
466 processing, storage, laboratory analysis, and instruments used for quantifying salivary hepcidin
467 concentrations are reported in Supplementary File 3 and the summary of results is highlighted in
468 Supplementary File 5.

469 One study reported relatively lower hepcidin concentrations in saliva than serum (45). In this
470 study, there was no correlation between salivary ferritin level and salivary hepcidin level (p-
471 value > 0.05). However, they didn't report the correlation coefficient (45). Another study
472 confirmed the presence of hepcidin-25 in saliva, with detected levels (Mean \pm SD) of 3.39 ± 2.83
473 ng/mL and a range of < 0.9-11.8 ng/mL (108). The combined Mean \pm SD of hepcidin was $1.85 \pm$
474 2.16 ng/mL among 105 adult participants enrolled in both studies on salivary hepcidin (110).

475 **d. Immunoglobulin A**

476 Immunoglobulin A (IgA) is an antibody within the immune system that plays a critical role in the
477 initiation of inflammation, which occurs through the formation of IgA complexes (111). Studies
478 have shown that IgA plays a critical role in maintaining gut homeostasis by regulating the initiation
479 of inflammation at both mucosal and non-mucosal sites (111). IgA deficiency has been linked to
480 autoimmune disorders, skin infections, and asthma (111). Unfortunately, there are currently no
481 treatments for IgA deficiency (111). IgA responses are modulated by dietary nutrients such as
482 fiber, lipids, glutamine, and vitamin A, as well as by microbially derived metabolites such as ATP
483 and short-chain fatty acids; therefore, they are closely related to nutrition (112). In an existing
484 study, a correlation between zinc and vitamin A deficiency in erythrocytes was recorded in patients
485 with IgA deficiency (113). However, further investigation is needed to validate its reliability. IgA
486 is found in the mucous membranes throughout the respiratory, gastrointestinal, and urogenital

487 tracts (114). It can also be found in your saliva. However, research on salivary or serum IgA as a
488 biomarker for assessing inflammatory/nutritional disorders is limited. Evidence is also scarce on
489 the correlations between serum and salivary IgA levels. Current research gaps for saliva IgA
490 analysis also include missing data and salivary inflammatory levels below detectable limits, and a
491 lack of standardized methodologies for salivary collection and storage. Only a few studies have
492 examined the correlation between salivary IgA and systemic markers of inflammation or
493 nutritional deficiency, making it difficult to assess its diagnostic accuracy (113).

494 We identified 11 studies that assessed salivary IgA concentrations (68, 115-124). The methods of
495 saliva collection, processing, storage, laboratory analysis, and instruments used for quantifying
496 salivary IgA concentrations are reported in Supplementary File 3. Seven studies were cross-
497 sectional studies, and four studies were randomized trials. Data on serum IgA levels are also scarce
498 in the included studies. Only three studies reported serum IgA concentrations. However, none of
499 the studies examined the correlations between salivary and plasma IgA concentrations. The
500 summary of results is highlighted in Supplementary File 5.

501 Salivary IgA was not detectable in two studies. Two studies indicated that nutritional interventions
502 (e.g., zinc supplementation or probiotics) might help improve immune response by modulating
503 salivary IgA levels in children with nutritional impairments. One study reported that prebiotic
504 intervention had no effect on salivary sIgA levels in adults with overweight (123). The results from
505 two studies showed no significant difference in salivary IgA between the groups with different
506 nutritional impairments (68, 120). One study found lower salivary IgA levels in undernourished
507 children compared to their well-nourished counterparts (121). In contrast, one study observed that
508 stunted infants had significantly higher salivary IgA levels than those with normal length-for-age
509 Z-scores (115). One study reported significantly higher salivary sIgA levels in adolescents with

510 obesity (116). Another study found that salivary IgA levels were positively correlated with BMI
511 and fat percentage across all participants. In this study, salivary osmolality was also significantly
512 correlated with salivary IgA in children with overweight or obesity (117). These findings suggest
513 that obesity in children may be linked to increased salivary IgA levels, potentially reflecting altered
514 mucosal immune responses and systemic changes associated with overweight or obesity.
515 Nonetheless, further prospective and longitudinal studies are needed to confirm this explanation.

516 **e. Cytokines**

517 Cytokines are known as signaling molecules of the immune system. They play an important role
518 in the immunological response against pathogens and other antigens by binding to receptors on the
519 surface of target cells. Cytokines are commonly affected by nutritional impairments. Nutrient
520 deficiencies affect the production and activity of cytokines, leading to altered immune response.
521 Therefore, cytokines are evaluated in nutrition studies or clinical settings in order to assess the
522 impact of inflammation on nutritional status and immune function. Cytokines are commonly
523 measured in blood samples; however, recent evidence suggests that saliva can be a potential
524 biological sample for the assessment of cytokines. We have identified 27 studies that assessed
525 salivary cytokines. Studies included in this review mostly reported TNF-alpha and IL-6 in saliva
526 samples. In addition to these two cytokines, the included studies also assessed other cytokines,
527 including IL-1 β , IL-1Ra, IL-8, IL-10, IL-1Ra, MCP-1, NGF, sCD40L, MMP-9, MMP-2, PTX-3,
528 PAI-1, VEGF, siCAM-1, sPLA2-IIA, Lp-PLA2, Serpin A12, TNF-R1, and TLR2. Therefore, we
529 report the findings in three subheadings: TNF-alpha, IL-6, and other cytokines.

530 **• TNF-alpha**

531 Tumor Necrosis Factor alpha (TNF- α) is a pro-inflammatory cytokine involved in the regulation
532 of immune responses (125, 126). TNF- α , produced primarily by macrophages as well as adipocytes

533 and T cells, triggers inflammation and cell death through receptor-mediated signaling (126).
534 Excess TNF- α can lead to chronic inflammation, autoimmune diseases, and metabolic syndrome
535 (126, 127). In obesity, elevated levels of TNF- α contribute to chronic low-grade inflammation and
536 are associated with insulin resistance and metabolic dysregulation (126). TNF- α concentration is
537 commonly measured in the blood to assess the severity of these diseases (128). However, with a
538 short half-life, TNF- α is rapidly eliminated from the blood, resulting in lower serum concentrations
539 (129). There is limited research measuring TNF- α levels in saliva to assess nutrition-related
540 inflammatory conditions. Salivary TNF- α measurement offers a promising non-invasive method
541 for assessing inflammation, but its reliability requires further validation. We identified eleven
542 studies that measured TNF- α concentrations (3, 130-139). The methods for sample collection,
543 processing, storage, laboratory analysis, and instruments used to quantify salivary TNF- α
544 concentrations are reported in Supplementary File 3.

545 The results of the studies on salivary TNF- α are highlighted in Supplementary File 5. The results
546 from the included studies suggest that TNF- α has the potential to serve as a non-invasive tool to
547 monitor the inflammatory changes in individuals with overweight or obesity. Five studies observed
548 elevated salivary TNF- α levels among participants with overweight or obesity. Two studies did
549 not observe any difference in salivary levels of TNF- α between normal-weight individuals and
550 those with overweight or obesity. One study observed significant positive correlations between
551 body mass index and salivary TNF- α concentrations; however, the sample size was small, limiting
552 the interpretability of the findings (139). Only two studies examined the correlation between
553 salivary and serum levels of TNF- α , and neither observed a significant correlation (3, 131). In the
554 remaining studies, serum TNF- α levels were not directly compared with salivary TNF- α levels,

555 thereby making it difficult to determine the accuracy of salivary TNF- α in predicting inflammation
556 or disease states.

557 • **IL-6**

558 Interleukin-6 (IL-6) is involved in immune regulation, inflammation, and hematopoiesis (140). At
559 the site of inflammation, IL-6 is produced to trigger acute phase protein production and responses,
560 as well as the transition from innate to adaptive immunity (140). Elevated IL-6 levels are
561 implicated in various metabolic conditions, including diet-induced obesity in response to
562 metabolic stress (141). IL-6 is frequently measured in serum to assess inflammatory conditions;
563 however, its involvement in both pro-inflammatory and anti-inflammatory pathways limits the
564 reliability of serum levels alone as definitive indicators of inflammation (142). IL-6 is not routinely
565 measured in the clinical setting since its standardization is low, and assessment is costly compared
566 to other routinely used inflammatory biomarkers (143). Additionally, research on salivary IL-6 as
567 a biomarker of nutrition-related inflammatory conditions is currently limited. Salivary IL-6
568 measurement offers a promising non-invasive method for assessing inflammation, but its
569 reliability requires further validation. We identified 18 studies that measured IL-6 concentrations
570 (3, 100, 130-133, 136, 144-154). The methods for sample collection, processing, storage,
571 laboratory analysis, and instruments used to quantify salivary IL-6 concentrations are reported in
572 Supplementary File 3. The results of the studies that investigated salivary IL-6 levels are
573 summarized in Supplementary File 5. Only three studies examined the correlation between salivary
574 and serum levels of IL-6; however, none found a significant correlation between salivary and
575 serum IL-6 concentrations (3, 100, 131). Several studies reported elevated salivary IL-6 levels in
576 individuals with overweight or obesity compared to normal-weight controls. The findings
577 underscore the need for more well-designed studies with standardized methods to confirm the

578 utility of IL-6 as a potential biomarker for the assessment of overweight or obesity. Evidence
579 regarding the effects of nutritional interventions (e.g., zinc supplementation or turmeric
580 consumption) on salivary IL-6 levels was inconsistent across studies. Some studies reported
581 elevated salivary concentrations of IL-6 in individuals with inflammatory conditions, such as PD,
582 gingivitis, and other forms of periodontal inflammation. These findings suggest that salivary IL-6
583 may reflect the underlying chronic inflammatory condition, irrespective of individual health status.
584 However, most of the included studies were observational in design, and results were not
585 consistent across study populations and clinical contexts. This inconsistency suggests that the
586 reliability of salivary IL-6 as an inflammatory biomarker may depend on the specific disease
587 context and population studied.

- 588 • **Other cytokines**

589 We identified 22 studies assessing salivary cytokines other than TNF-alpha and IL-6. The
590 summary of studies with other cytokines and the findings are reported in Supplementary File 5.
591 Similar to TNF- α and IL-6, findings were heterogeneous across studies and varied among different
592 populations. Only a few studies reported statistically significant differences in cytokine levels
593 between healthy controls and individuals with specific conditions. Similarly, few studies examined
594 correlations between cytokine concentrations in saliva and corresponding serum levels. However,
595 the results were inconsistent, limiting our ability to draw conclusions regarding the diagnostic
596 utility of these salivary cytokines relative to their blood-based counterparts.

597 **Discussion**

598 This review synthesized current evidence on the feasibility and use of salivary biomarkers for the
599 assessment of nutrition (e.g., ferritin, iron, zinc, calcium, vitamin A, vitamin B12, folic acid,
600 vitamin C, vitamin D, and vitamin E) and inflammation (e.g., CRP, AGP, Hcpidin, IgA, and

601 cytokines), from 76 articles, across 26 countries involving 5425 children and 5617 adults. We
602 cataloged and summarized the results from 33 studies assessing ferritin, iron, zinc, calcium,
603 vitamin A, vitamin B12, vitamin D, vitamin C, and vitamin E in saliva samples. We didn't find
604 any study assessing salivary sTfR. Only one study assessed salivary folic acid; however, the level
605 was above the LOD. Additionally, we found 43 studies evaluating salivary inflammatory
606 biomarkers such as CRP, AGP, hepcidin, IgA, and cytokines within the context of nutritional
607 impairments. While most of the biomarker values were detectable in saliva samples, their
608 application in nutritional surveillance and profiling of inflammatory conditions remains
609 challenging, especially in settings with a high burden of nutritional impairments, inflammation,
610 and infection. We found inconsistencies in the salivary biomarker values across most studies
611 included in this review. For example, in healthy controls, three studies reported higher salivary
612 ferritin levels compared to serum ferritin, whereas two studies showed the opposite trend. In
613 patients with iron deficiency anemia (IDA), three studies found salivary ferritin levels to be
614 consistently higher than serum ferritin levels; however, only one of these studies examined the
615 correlation between the two and reported a strong positive relationship. Similarly, one study
616 conducted in children found higher salivary iron levels than serum iron, while two studies in adults
617 reported higher serum iron concentrations. Four studies assessed vitamin D biomarkers in both
618 saliva and serum. Two of these reported higher salivary levels than serum levels, while the other
619 two observed the opposite pattern. Overall, the results for most biomarkers remain inconsistent,
620 and only a limited number of studies have investigated the correlation between salivary and serum
621 concentrations for each biomarker. The current evidence is also weakened by substantial
622 heterogeneity in study design, sample characteristics, and analytical methods across studies
623 evaluating salivary biomarkers. The variability in the methods for sample collection, processing,

624 storage, laboratory analysis, and quantification techniques raises concerns regarding the
625 comparability and generalizability of the results. Therefore, more well-designed clinical and
626 longitudinal studies using standardized methodologies are needed to determine the diagnostic
627 accuracy and clinical utility of salivary biomarkers. Additionally, diagnostic test accuracy research
628 is needed to assess the feasibility of saliva-based screening tests, compared to reference standards
629 in blood, for the assessment of nutrition and inflammatory biomarkers, both in primary care
630 settings and population-level studies.

Text Box 1. The criteria required for a biomarker to be measured in saliva

- It should be present at a detectable level in saliva
- The concentration should be stable within the salivary matrix
- It should reflect the body's physiological and pathological states
- Sample collection should be easy, safe, and comfortable for the participants
- Sample collection, processing, transportation, storage, and laboratory analysis should be performed using standardized protocols and techniques
- The laboratory assay methods should be validated and optimized to minimize measurement errors
- The detection method needs to be sensitive, specific, and reproducible across individuals and different populations
- The concentration should be within the sensitivity range of available detection methods
- The measurements should show low intra- and inter-assay variability
- The biomarker should correlate with the corresponding blood biomarker
- The findings should be reliable and clinically meaningful, with optimal diagnostic accuracy
- The assessment should be cost-effective to adopt in routine clinical and primary care practice

631 The criteria required for a biomarker to be measured in saliva are listed in Text Box 1. Ideally, for
632 a biomarker to be considered measurable in saliva, its concentration should be stable within the
633 salivary matrix (155). The oral microbiome and endogenous salivary components, including
634 enzymes, hormones, and epithelial cells, may influence saliva-based diagnostic assays (155). For
635 example, proteolytic enzymes may influence the degradation of targeting proteins, and microbial
636 activity may alter the concentrations of certain metabolites, leading to inaccurate measurements of
637 salivary analytes (155, 156). Therefore, the biomarker to be measured in saliva must resist
638 degradation by microbial and enzymatic activity (155). Additionally, the biomarker should be

639 present at a detectable level in saliva for assessing nutrition or inflammation status and should
640 reflect the body's physiological and pathological states to ensure clinical relevance (157). It should
641 also correlate with corresponding blood biomarkers (155). The detection method needs to be
642 sensitive, specific, and reproducible, accounting for the variability in salivary pH, flow rates, oral
643 health conditions, underlying diseases, and other biological determinants (155, 158, 159).
644 Moreover, the sample collection protocols, processing and storage techniques, and laboratory
645 analysis methods should be standardized to account for the intra- and inter-individual variability
646 in salivary biomarker concentrations (155, 158). Appropriate statistical tests with adjustment for
647 all potential confounders are also needed to address the issue of intra- and inter-individual
648 variability. Additionally, multiple other challenges need to be addressed before salivary tests can
649 be implemented routinely in clinics, schools, or communities. Figure 3 highlights several
650 methodological gaps in the current understanding of salivary biomarkers for assessing nutrition
651 and inflammation, particularly in low-resource settings.

652 **A. Discovery-based gaps**

653 To realize the potential of salivary biomarkers for nutrition and inflammation, we have identified
654 several discovery-based gaps in this review that need to be addressed. First, the source of analytes
655 measured in saliva samples is unclear. Salivary biomarkers were measured in unstimulated whole
656 saliva in most of the included studies. Perhaps, the analytes enter saliva by diffusing through the
657 cells of the salivary glands or by ultrafiltration through the tight junctions (160). However, further
658 investigation is required to confirm the source of the different nutritional and inflammatory
659 biomarkers assessed in saliva. Furthermore, many biomarkers are present at substantially lower
660 concentrations in saliva than in blood (161, 162). These physiologically lower levels can challenge
661 accurate quantification, may compromise detectability, and complicate interpretation of the

662 findings (162). Even minor variations in sample collection, handling, storage, or analytic
663 procedures can introduce measurement error and limit reproducibility (162). Hence,
664 standardization of collection and processing protocols, together with optimization of assay
665 methodologies using highly sensitive platforms, is essential to ensure reliable and clinically
666 meaningful results. It is also essential to determine whether the concentrations of these biomarkers
667 are influenced by salivary pH, production, and flow rates. Salivary pH can alter the assay results
668 (162). On the other hand, a high salivary flow rate dilutes the sample, leading to an inaccurate
669 assessment of the biomarkers. When feasible, salivary pH and flow rate data can be used to adjust
670 the concentrations of salivary biomarkers. Second, nutrition biomarkers indicate intake, status, or
671 function. While blood and some urinary biomarkers are well established for assessing these
672 aspects, there are still gaps in categorizing salivary biomarkers as indicators of intake, status, or
673 different functions (33). Some salivary biomarkers for nutrition assessment may reflect
674 micronutrient status, but further research is needed to determine how to use them for assessing
675 intake and various functions. Third, there is limited evidence on the correlation between salivary
676 and blood biomarkers for nutritional and inflammatory assessments. Establishing these
677 correlations is essential to validate saliva as a reliable substitute for blood, especially in settings
678 where blood collection is logistically challenging or culturally sensitive. Without this comparative
679 assessment and validation, the clinical and public health relevance of salivary biomarkers remains
680 uncertain. Fourth, our findings underscore the lack of data on salivary biomarkers among children,
681 adolescents, and women of reproductive age (WRAs) in low-resource settings. Most available
682 studies were conducted in adult populations or clinical environments, limiting the generalizability
683 of the findings in different geographic settings. This is particularly concerning given the high
684 burden of malnutrition and inflammation among children in low- and middle-income countries.

685 Fifth, the diagnostic accuracy of salivary biomarkers has not been systematically evaluated in
686 populations with a high burden of infections and chronic inflammation. In such contexts,
687 inflammation can alter the concentration and detectability of nutritional biomarkers, potentially
688 leading to misinterpretation and diagnostic errors. Understanding how these markers behave in
689 saliva under conditions of concurrent infection and malnutrition is essential for developing reliable
690 screening tools. Finally, another important gap is the lack of evidence regarding the ratio-based
691 indices in salivary biomarker research. In blood, indices such as the sTfR:ferritin ratio have proven
692 valuable in distinguishing iron deficiency from inflammation-induced changes. The potential to
693 develop similar composite indices using salivary biomarkers remains unexplored. These tools
694 could enhance diagnostic precision, particularly in settings where both malnutrition and infection
695 are prevalent.

696 **B. Sample collection, processing, and storage gaps**

697 This review identified several methodological issues in the aspects of sample collection,
698 processing, and storage that may compromise the reliability and comparability of salivary
699 biomarkers in nutrition and inflammation assessment. One major challenge is the variation in
700 saliva collection methods. The variability in collection methods (e.g., stimulated vs. unstimulated,
701 or drooling vs. spitting) and duration of sample collection can affect the levels and determination
702 of salivary biomarkers of interest (21). Nevertheless, there are no established methods and
703 standardized protocols for collecting saliva samples. Additionally, most current methods have not
704 been optimized or validated for participants with different age groups and individuals with disease-
705 related physiological alterations, which may influence the volume, flow rate, and concentrations
706 of the collected samples (12). We found only a few studies that have standardized their collection
707 protocols. Most studies included in this review collected unstimulated whole saliva samples from

708 the participants. This is the most acceptable and convenient way for clinical settings and research
709 studies. The whole saliva is a complex mixture of various biocomponents secreted by different
710 salivary glands (12). The secretions from these glands differ in composition, and thus, the
711 detectable range and diagnostic values can be variable (12). However, some studies collected
712 stimulated saliva samples from the participants. Saliva origin, production rate, and composition
713 may vary between unstimulated and stimulated samples (21). However, it is unclear whether
714 unstimulated or stimulated saliva offers more reliable and reproducible measurements of nutrition
715 and inflammatory biomarkers. Further investigation is required to compare unstimulated and
716 stimulated saliva samples for the measurement of nutritional and inflammatory biomarkers.

717 The passive drool method is considered a standard practice and can be easily performed for adults,
718 with minimal limitations for children aged over 5 years (21, 163, 164). However, this method may
719 not be suitable for children under three years old (165). It is because the passive drool technique
720 requires patience and active cooperation from the children. It may also cause discomfort in younger
721 children. Therefore, some studies suggest using passive drool methods for saliva collection in
722 children younger than three years under the supervision of study personnel (166). Other studies
723 recommend applying the suction method or collecting an oral swab instead in young children (165,
724 166). However, some analytes, including salivary CRP, IgA, and cytokines, may not be detectable
725 if analyzed in oral swabs collected from children. We found various methods and durations for
726 collecting saliva samples from participants of different age groups. The spitting method and
727 passive drool technique were the most commonly used methods in the included studies. These
728 methods may provide undiluted saliva and are less likely to underestimate salivary analytes.
729 However, alternative techniques, such as the use of cotton pads or swabs, were also found to be
730 used in some studies. These methods have limitations as they can alter biomarker concentrations

731 due to the position of the swab in the oral cavity and dilution effects (21, 163). Absorbing the
732 saliva specimen on cotton may also interfere with substances in cotton, leading to over- or
733 underestimation of the analytes measured in saliva (160). It is important to standardize the swab
734 placement protocol for studies that intend to collect saliva samples using cotton swabs. Salivary
735 production and composition are also influenced by the time of day when the specimen is collected
736 (163). Diurnal variation may also affect the interpretation of the saliva assay results (21). While
737 most studies collected saliva samples in the morning, some studies collected at daytime before or
738 after lunch, or in the evening. One approach can be collecting saliva samples early in the morning
739 to avoid variation in the salivary analytes caused by diurnal effects. It is important to maintain the
740 same time every day for all the participants of the study. If time and resources allow, saliva samples
741 can be collected at two time points in a day (e.g., morning and evening) to account for diurnal
742 variation.

743 We also observed variability in salivary sample collection regarding the collection site (e.g., home,
744 school, or clinic), duration of food and drink restrictions (e.g., 30 minutes, 1 hour, 2 hours, or
745 overnight for 12 hours), participant position during collection, and collection device across studies,
746 which may influence sample quality and volume. If samples are collected at home, participants
747 and/or caregivers should be instructed on the collection protocol and properly counseled to ensure
748 standardized collection and timely transportation of the samples to the laboratory. The same
749 protocol and collection device should be used throughout the study for all participants to avoid
750 variability. At least 1 mL of saliva should be collected from each participant, regardless of the
751 collection site, age, or disease status. This minimum volume is required to ensure the detection of
752 low-abundance biomarker materials in the saliva sample. Also, a sufficient volume is needed to
753 fulfill the requirements of sample processing and laboratory analysis methods. Furthermore, an

754 adequate volume of saliva sample is needed to calculate the saliva flow rate and ensure the
755 accuracy and reliability of the findings (13). Another challenge of saliva samples is standardizing
756 the sample processing and storage protocols (160, 167). We found substantial variation in sample
757 processing in the studies included in this review. It is recommended to process the saliva samples
758 as soon as possible after collection. Processing of saliva samples within 1 hour may prevent
759 significant sample degradation (168). However, most studies did not report the duration from
760 saliva sample collection to processing. Only a few studies reported that they processed the samples
761 within 2 hours of collection. It is important to maintain a window of less than 2 hours from sample
762 collection, transportation to the laboratory, and processing of samples to maintain sample integrity.
763 The use of preservatives or additives such as protease and dipeptidyl peptidase-4 (DPP4) inhibitors
764 during or after collection was inconsistent across studies included in this review. These inhibitors
765 may help to prevent the enzymatic degradation of proteins and peptides, yet only a few studies
766 have used them. This inconsistency poses a risk to the accuracy of measurements, particularly for
767 protein-based biomarkers. Another concern is the reduced salivary flow observed in patients with
768 certain conditions, such as asthma and autoimmune diseases. Lower saliva volumes can hinder
769 sample collection and reduce the concentrations of the biomarker of interest, further complicating
770 interpretation. Despite this, only a few studies adapted their protocols to account for patient-
771 specific limitations. Centrifugation of the saliva sample is a critical step to remove food materials,
772 blood, cellular debris, bacteria, and other contaminants (164). Although centrifugation was
773 performed in most studies, the parameters such as speed, temperature, and duration varied
774 significantly across the included studies. Some studies centrifuged samples immediately after
775 collection before storage, while others stored samples first and centrifuged on the day of laboratory
776 analysis. The lack of standardized sample processing and centrifugation methods may affect

777 sample quality and biomarker stability, which can further influence the downstream analysis of
778 saliva samples. Maintenance of optimal temperature during sample collection, transportation,
779 processing, and storage is crucial for the integrity and stability of salivary analytes. We observed
780 variable practices regarding the transportation temperature (e.g., on dry ice, ice box, liquid
781 nitrogen, and 4°C). Additionally, the protocol for sample storage also varied widely across studies.
782 While lower temperatures (e.g., -80 °C) are generally recommended to preserve biomarker
783 integrity (164), some studies stored samples at higher (i.e., 2-8 °C, -20 °C, -30 °C) or unspecified
784 temperatures. Temperature issues and inconsistent storage practices may lead to biomarker
785 degradation and variability in results and interpretation (164). Therefore, it is essential to
786 standardize protocols for sample handling, preparation, and storage. The standard practice for
787 saliva collection, processing, and storage is highlighted in Text Box 2.

Text Box 2. Standard Practice for Saliva Collection, Processing, and Storage

- Participants should not eat or drink anything for at least 30 minutes before saliva collection
- Participants should refrain from caffeine intake and tooth-brushing at least 60 minutes before saliva collection
- Study staff should document any consumption of caffeine, alcohol, nicotine, medications, and nutritional supplements before the sample collection
- Study staff should also document the presence of any oral or systemic diseases and any acute symptoms of diseases or inflammation before the sample collection
- Participants should rinse out their mouths with water to remove residual food particles
- After rinsing, the participants should wait at least 10 minutes before saliva collection to avoid dilution of salivary analytes
- Study staff and participants should wash their hands with soap and water and put on gloves before saliva collection
- For whole saliva collection, participants should be instructed to pool saliva naturally in the mouth and collect a minimum of 1 mL of saliva in each collection tube
- For the passive drool method, the participants should tilt their head forward and gently drool down the saliva into the collection tubes, preferably using a straw
- Participants should be careful so that the froth does not get aspirated
- Participants should not collect or produce saliva samples by clearing their throats
- Study staff should document the sample volume and the duration of sample collection to calculate the salivary flow rate
- Study staff should conduct a visual assessment of the samples immediately after collection to ensure the saliva sample is not contaminated with blood, mucus, food particles, or other substances
- Samples should be stored on ice or at -20°C and transported to the laboratory for processing, maintaining the cold chain, and using appropriate transport methods

- Upon arrival at the laboratory, samples should be processed immediately and stored in a freezer without delay
 - If the analysis is to be performed immediately, samples can be stored at room temperature for 30-90 minutes and at 4°C for 3-6 hours
 - If the analysis is to be performed within a month, freeze the samples at or below -20 °C
 - For long-term storage (> 3 months), freeze the samples at or below -80 °C

788 **C. Methodological challenges for laboratory analyses**

789 The existing evidence revealed that several methodological challenges persist in the laboratory
790 analysis of nutrition- and inflammation-related saliva biomarkers. Evidence supporting the
791 analytical validity of many salivary biomarkers remains limited, with insufficient standardization
792 and incomplete reporting of key assay performance characteristics. These challenges limit the
793 reproducibility, comparability, and overall reliability of findings across studies. One major issue
794 is the variability in analytical techniques used to measure salivary biomarkers. Furthermore, there
795 remains limited information regarding analysis methods, instruments, reagents, and the best
796 practices for handling and preparation of saliva samples required to implement salivary biomarker
797 analysis in both clinical and community settings (167, 169).

798 One methodological challenge is the analysis of salivary zinc and calcium biomarkers together.
799 While atomic absorption spectrophotometry has been commonly employed due to its accessibility
800 and simplicity, this method is susceptible to interference from calcium-rich precipitates. This
801 interference can lead to inaccurate estimations of total calcium levels in saliva, which in turn
802 affects the interpretation of results. The lack of a standardized and validated method for salivary
803 calcium assessment remains a key barrier to reliable biomarker development and application (63).
804 Another methodological gap lies in the analysis of salivary vitamins. For example, one study
805 attempted to detect vitamins A, B12, and D in saliva but was unsuccessful (73). However, the
806 study did not report sufficient information about the analytical methods used, nor did it discuss
807 potential sources of error or limitations in detection. This lack of reporting limited our

808 understanding of whether the failure was due to low salivary concentrations, inadequate assay
809 sensitivity, or other technical constraints. Without such details, it is difficult to draw meaningful
810 conclusions or to guide future methodological improvements. These examples underscore the need
811 for rigorous validation of laboratory methods and more detailed reporting of analytical protocols
812 and limitations. Establishing standardized procedures and improving assay sensitivity are critical
813 steps toward enhancing the utility of salivary and other non-invasive biomarkers in nutrition and
814 inflammation research.

815 **D. Diagnosis and interpretability-related challenges**

816 It is challenging to use salivary biomarkers for the diagnosis of nutrient deficiencies and
817 inflammatory conditions linked to growth impairments. The quantification of biomarkers or
818 analytes in saliva does not indicate clinical significance or their utility in clinical practice.
819 Understanding the distinction between diagnostic tests and surveillance tests in saliva biomarkers
820 is important in the context of clinical decision-making and public health programs. There are no
821 age- and sex-specific reference values for salivary biomarkers, which restricts the ability to
822 interpret results meaningfully in clinical or community settings. Another challenge of using saliva
823 for diagnostic purposes is identifying disease-specific markers.

824 One of the main limitations of the studies included in this review is their reliance on cross-sectional
825 designs and the lack of longitudinal data, which may restrict our understanding of the temporal
826 relationships between salivary biomarker levels and various health outcomes. Evidence is also
827 limited regarding the sensitivity and specificity of tests conducted on saliva samples. Most of the
828 studies included in this review had small sample sizes, limiting the statistical power to detect
829 meaningful associations or differences across population subgroups. Larger, well-designed studies
830 are needed to establish normative data, to determine the reference ranges, and to assess the

831 sensitivity and specificity of salivary biomarkers for identifying nutritional deficiencies and
832 inflammatory states.

833 The use of saliva-based diagnostics may increase the risk of false-positive or false-negative results
834 due to methodological heterogeneity and biological variability. However, this limitation can be
835 addressed by standardizing sample collection and analytical procedures, validating assays against
836 established serum markers, and implementing appropriate quality control measures. Another
837 significant limitation is the relatively low R^2 values comparing salivary to serum biomarkers. This
838 indicates that the independent variables cannot adequately explain the proportion of variance in
839 the dependent variable, which, in most cases, is salivary biomarkers. It is crucial to gather
840 information on other variables that may play a critical role in explaining the outcomes. Factors
841 such as oral health conditions, tobacco or alcohol use, and diet can change the composition of
842 salivary analytes (170-172). A diet containing high sugar and/or high caffeine may affect salivary
843 pH and alter the microbial composition of the oral cavity (21). Some salivary biomarkers, such as
844 CRP, AGP, hepcidin, IgA, and cytokines, can be influenced by age, sex, hormones, mood, stress,
845 infection, and disease states. Furthermore, the interpretation of salivary biomarker concentrations
846 is complicated by physiological factors such as production, flow rate, and dilution (160).
847 Variability in saliva production, affected by pH, hydration status, time of day, and whether saliva
848 is collected at rest or under stimulation, can introduce significant measurement issues (160). Some
849 medications, for example, anti-hypertensive drugs, may cause dry mouth by preventing salivary
850 glands from producing adequate saliva (173, 174). Additionally, certain diseases and medical
851 conditions, such as high blood sugar and elevated blood pressure, may alter the oral microbiome
852 profiles and disrupt saliva production (173-175). Therefore, it is important to control for all
853 potential confounding factors (e.g., age, sex, time of the day, pH, hydration status, diet,

854 medications, and health issues) that might affect the salivary composition while interpreting the
855 findings of salivary nutritional and inflammatory biomarkers (160). However, data on clinical
856 history, oral health condition, dietary habits, nutrient intake, smoking, and alcohol consumption
857 were limited in most of the studies included in this review. The lack of data on these important
858 confounding variables, as well as the inability to adjust for them, limited the comparability of
859 findings across studies.

860 Nevertheless, the findings suggest the potential of saliva as a biological specimen to assess several
861 nutritional and inflammatory biomarkers. However, most studies included in this review have only
862 presented preliminary findings on the biomarkers of nutrition and inflammation. There remains a
863 gap in validating the salivary biomarkers in large cohorts and diverse population subgroups.
864 Additionally, evidence is limited regarding the comparability of salivary analytes to conventional
865 blood biomarkers. Therefore, it is unclear whether saliva samples can be used for the evaluation
866 and monitoring of micronutrient status and inflammatory conditions in different population
867 subsets. Further well-designed research with standardized methodologies is needed to identify and
868 validate salivary biomarkers of nutrition and inflammation for clinical, primary care, and
869 programmatic applications. We recommend large-scale, multicenter clinical trials and independent
870 validation studies to provide evidence for the clinical utility of salivary diagnostics in diagnosing
871 and/or monitoring nutritional status and inflammatory conditions. The studies should also assess
872 the diagnostic performance and accuracy of salivary biomarkers compared to conventional blood
873 biomarkers. Additionally, the integration of artificial intelligence (AI) and machine learning (ML)
874 approaches with salivary biomarker assessment may improve the accuracy, reliability, and
875 interpretability of these measures.

876 **E. Future directions**

877 Despite the gaps we discussed above, this review highlights the potential of salivary biomarkers
878 for assessing nutrition and inflammation in different settings. Although the current evidence base
879 is limited and findings remain inconsistent for many biomarkers, our review suggests that several
880 salivary biomarkers could be assessed in research studies alongside their corresponding blood
881 biomarkers. For instance, salivary ferritin can be measured using the chemiluminescent
882 microparticle immunoassay (CMIA), a widely used and standardized method for quantifying
883 ferritin concentrations in clinical and field settings. The studies included in this review indicate
884 that this technique can also be applied to saliva samples. However, important questions remain
885 regarding analytical sensitivity, assay optimization for saliva matrices, and reproducibility across
886 laboratories. Addressing these gaps will be essential before salivary ferritin can be reliably
887 integrated into broader research or clinical applications.

888 Our review also suggests that larger clinical studies are needed to collect and analyze saliva
889 samples from diverse population subsets across different geographic locations, following
890 standardized protocols to estimate key nutritional and inflammatory biomarkers. These studies
891 should be used to address the gaps mentioned above, enhance the diagnostic performance and
892 accuracy of salivary biomarkers, and compare their concentrations with traditional blood
893 biomarkers to confirm the utility of salivary diagnostics compared to current methods. Advances
894 in machine learning analysis can also help identify the most effective salivary biomarkers or
895 clusters of salivary biomarkers capable of predicting nutritional and inflammatory disorders.
896 Machine learning algorithms may also guide how to adjust for inflammatory biomarkers while
897 evaluating micronutrient biomarkers that are often affected by infection and inflammation, such
898 as serum ferritin and retinol-binding protein. All these efforts would facilitate the use of salivary
899 diagnostics for nutrition and inflammation assessment in various settings.

900 Figure 4 illustrates the applications of saliva-based diagnostics for evaluating nutritional status and
901 inflammatory conditions across different settings. Due to their non-invasiveness, affordability, and
902 higher acceptance, salivary diagnostics can be easily implemented in community, school, and/or
903 primary care clinical settings. In the community, saliva-based diagnostics can be used for
904 surveillance or programmatic assessment of micronutrient status, as well as for evaluating
905 interventions aimed at improving micronutrient levels. In schools, saliva diagnostics can be
906 employed for screening micronutrient status or monitoring children at risk of micronutrient
907 malnutrition, and for evaluating targeted interventions or school meal programs designed to
908 improve nutritional status in school-going children. In primary care or clinical settings, saliva
909 diagnostics can be used for triage or rapid assessment of micronutrient levels, and continuous
910 monitoring of nutritional status in hospitalized patients. Saliva biomarkers can also be useful for
911 assessing treatment responses in clinical practice. If larger studies demonstrate sufficient
912 diagnostic performance, biosensor or lateral flow-based point-of-care devices can be developed
913 for salivary diagnostics. These innovations would enhance public health programs in primary care,
914 community, and school settings and improve clinical care.

915 **Conclusions**

916 In summary, saliva contains many nutritional and inflammatory biomarkers and has potential
917 utility as a noninvasive matrix for primary care in the context of nutrition and inflammation
918 assessment. However, evidence comparing the biomarkers in saliva to their counterparts in
919 currently accepted biomatrices, including blood and urine, remains scant. The methodological
920 inconsistencies underscore the need for standardized, validated protocols for saliva sample
921 collection, processing, and storage. Harmonization of these procedures is essential to ensure the
922 reproducibility and clinical utility of salivary biomarkers in assessing nutritional and
923 inflammatory status. Additionally, analytical performance, such as sensitivity and specificity of

924 the tests, is a key issue that might affect the decision to determine whether saliva-based
925 approaches are sufficient to achieve clinical benefits. Larger studies with adequate sample size,
926 both in clinical and community settings, are crucial for guiding not only implementation
927 decisions but also the development of the saliva-based assays and point-of-care diagnostic tools.
928 Future research should also prioritize studies in children, adolescents, and WRAs both in the
929 USA and in international settings, standardize saliva sample collection, processing, and storage
930 methods, emphasize in-depth methodological reporting, and examine the correlation between
931 salivary and serum biomarker concentrations to further understand whether salivary biomarkers
932 can be a reliable, inexpensive, and non-invasive alternative for assessing nutritional and/or
933 inflammatory disorders. Addressing the gaps discussed in this review is essential to harness the
934 full potential of saliva-based diagnostics in the assessment of nutritional status and inflammatory
935 conditions in different population subsets and various settings.

936 **Acknowledgements**

We acknowledge the support of Matthew Kibbee, Natasha Bishop, and Elizabeth DiGiovine, who reviewed and provided feedback on the search strategy. We also acknowledge the support of Brooke Overholt, Beatrice Juskeviciute, and Lilly Smith, who helped with screening and data extraction. Finally, we acknowledge funding support from the Eunice Kennedy Shriver National Institute of Child Health and Human Development under award number R21HD103974, the National Institute of Biomedical Imaging and Bioengineering and Fogarty International Center of the National Institutes of Health under Award Number U54EB034654.

Author contributions

The authors' responsibilities were as follows: SMF, DE, JLF, SM: conceptualized and designed this research; SMF, MM, MM, NZ, MA: performed the relevant literature search of the current

evidence and screening of articles, acquisition of study reports, study selection, data extraction, synthesis of results; and all authors were responsible for writing the original draft and reviewing and editing the manuscript. All authors read and approved the final manuscript.

Data Availability:

No datasets were generated or analyzed during the current study.

Funding: Research reported in this publication was supported by the Eunice Kennedy Shriver

National Institute of Child Health and Human Development under award number R21HD103974 and the National Institute of Biomedical Imaging and Bioengineering and Fogarty International Center of the National Institutes of Health under Award Number U54EB034654 - PORTENT: A Center for Point of Care Technologies for Nutrition, Infection, and Cancer. PORTENT is a member of the POCTRN+ Network. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author Disclosures: Corresponding authors will be queried for their own and their co-authors' conflict of interest disclosures during the manuscript submission process using the Declaration of Interests tool (<https://declarations.elsevier.com/>). The tool will generate a Word file for upload with your manuscript submission.

Declaration of Generative AI and AI-assisted technologies in the writing process:

Not applicable

References

- 937 1. Wilson ML, Fleming KA, Kuti MA, Looi LM, Lago N, Ru K. Access to pathology and laboratory medicine
938 services: a crucial gap. *The Lancet*. 2018;391(10133):1927-38.
- 939 2. Madimenos FC, Gildner TE, Eick GN, Sugiyama LS, Snodgrass JJ. Bringing the lab bench to the field: Point-
940 of-care testing for enhancing health research and stakeholder engagement in rural/remote, indigenous, and resource-
941 limited contexts. *American Journal of Human Biology*. 2022;34(11):e23808.

- 942 3. Tvarijonaviciute A, Martinez-Lozano N, Rios R, de Teruel MCM, Garaulet M, Cerón JJ. Saliva as a non-
 943 invasive tool for assessment of metabolic and inflammatory biomarkers in children. *Clinical Nutrition*.
 944 2020;39(8):2471-8.
- 945 4. Desai GS, Mathews ST. Saliva as a non-invasive diagnostic tool for inflammation and insulin-resistance.
 946 *World journal of diabetes*. 2014;5(6):730.
- 947 5. Kessler K, Hornemann S, Rudovich N, Weber D, Grune T, Kramer A et al. Saliva samples as a tool to study
 948 the effect of meal timing on metabolic and inflammatory biomarkers. *Nutrients*. 2020;12(2):340.
- 949 6. Williamson S, Munro C, Pickler R, Grap MJ, Elswick R. Comparison of biomarkers in blood and saliva in
 950 healthy adults. *Nursing research and practice*. 2012;2012.
- 951 7. Tiwari M. Science behind human saliva. *Journal of natural science, biology, and medicine*. 2011;2(1):53.
- 952 8. Ilea A, Andrei V, Feurdean CN, Băbțan A-M, Petrescu NB, Cămpian RS et al. Saliva, a magic biofluid
 953 available for multilevel assessment and a mirror of general health—A systematic review. *Biosensors*. 2019;9(1):27.
- 954 9. Genco RJ. Salivary diagnostic tests. *The Journal of the American Dental Association*. 2012;143:3S-5S.
- 955 10. Chojnowska S, Baran T, Wilińska I, Sienicka P, Cabaj-Wiater I, Knaś M. Human saliva as a diagnostic
 956 material. *Advances in medical sciences*. 2018;63(1):185-91.
- 957 11. Dawes C, Pedersen AL, Villa A, Ekström J, Proctor GB, Vissink A et al. The functions of human saliva: A
 958 review sponsored by the World Workshop on Oral Medicine VI. *Archives of oral biology*. 2015;60(6):863-74.
- 959 12. Aljerf L, Mashlah A. Characterization and validation of candidate reference methods for the determination
 960 of calcium and magnesium in biological fluids. *Microchemical Journal*. 2017;132:411-21.
- 961 13. Liao C, Chen X, Fu Y. Salivary analysis: An emerging paradigm for non-invasive healthcare diagnosis and
 962 monitoring. *Interdisciplinary Medicine*. 2023;1(3):e20230009.
- 963 14. Zhou Y, Liu Z. Saliva biomarkers in oral disease. *Clinica Chimica Acta*. 2023;548:117503.
- 964 15. Bel'skaya L, Sarf E, Kosenok V. Correlation interrelations between the composition of saliva and blood
 965 plasmal norm. *Klinicheskaia Laboratornaia Diagnostika*. 2018;63(8):477-82.
- 966 16. Javaid MA, Ahmed AS, Durand R, Tran SD. Saliva as a diagnostic tool for oral and systemic diseases. *J Oral*
 967 *Biol Craniofac Res*. 2016;6(1):66-75.
- 968 17. Loo JA, Yan W, Ramachandran P, Wong DT. Comparative human salivary and plasma proteomes. *J Dent*
 969 *Res*. 2010 Oct;89(10):1016-23.
- 970 18. Romano F, Castiblanco A, Spadotto F, Di Scipio F, Malandrino M, Berta GN et al. ICP-mass-spectrometry
 971 ionic profile of whole saliva in patients with untreated and treated periodontitis. *Biomedicines*. 2020;8(9):354.
- 972 19. Martina E, Campanati A, Diotallevi F, Offidani A. Saliva and oral diseases. *Journal of clinical medicine*.
 973 2020;9(2):466.
- 974 20. Malamud D. Saliva as a diagnostic fluid. *BMJ: British Medical Journal*. 1992;305(6847):207.
- 975 21. Bhattarai KR, Kim H-R, Chae H-J. Compliance with saliva collection protocol in healthy volunteers:
 976 strategies for managing risk and errors. *International journal of medical sciences*. 2018;15(8):823.
- 977 22. Paqué PN, Hjerpe J, Zuercher AN, Jung RE, Joda T. Salivary biomarkers as key to monitor personalized
 978 oral healthcare and precision dentistry: A scoping review. *Frontiers in Oral Health*. 2022;3:1003679.
- 979 23. Rocha ACS, Orlandini RK, Motta ACF, Pinheiro JB, Silva GAe, Oliveira VdC et al. Variability of salivary
 980 analytes under daily conditions and their implications for periodontitis biomarkers. *Frontiers in Dental Medicine*.
 981 2024;5:1369186.
- 982 24. Alamoudi A, Alamoudi R, Gazzaz Y, Alqahtani AM. Role of salivary biomarkers in diagnosis and detection
 983 of dental caries: a systematic review. *Diagnostics*. 2022;12(12):3080.
- 984 25. Fernandes L, Pacheco V, Borges L, Athwal H, de Paula Eduardo F, Bezinelli L et al. Saliva in the diagnosis
 985 of COVID-19: a review and new research directions. *Journal of Dental Research*. 2020;99(13):1435-43.
- 986 26. Hegde MN, Attavar SH, Shetty N, Hegde ND, Hegde NN. Saliva as a biomarker for dental caries: A
 987 systematic review. *Journal of conservative dentistry: JCD*. 2019;22(1):2.
- 988 27. Arias-Bujanda N, Regueira-Iglesias A, Balsa-Castro C, Nibali L, Donos N, Tomás I. Accuracy of single
 989 molecular biomarkers in saliva for the diagnosis of periodontitis: A systematic review and meta-analysis. *Journal of*
 990 *clinical periodontology*. 2020;47(1):2-18.
- 991 28. Nijakowski K, Surdacka A. Salivary biomarkers for diagnosis of inflammatory bowel diseases: A systematic
 992 review. *International journal of molecular sciences*. 2020;21(20):7477.
- 993 29. Bastías D, Maturana A, Marin C, Martínez R, Niklander SE. Salivary biomarkers for oral cancer detection:
 994 an exploratory systematic review. *International Journal of Molecular Sciences*. 2024;25(5):2634.

- 995 30. Kaufman E, Lamster IB. The diagnostic applications of saliva—a review. *Critical Reviews in oral biology &*
996 *medicine*. 2002;13(2):197-212.
- 997 31. Chiappin S, Antonelli G, Gatti R, De Palo EF. Saliva specimen: a new laboratory tool for diagnostic and
998 basic investigation. *Clinica chimica acta*. 2007;383(1-2):30-40.
- 999 32. Nagler RM, Hershkovich O, Lischinsky S, Diamond E, Reznick AZ. Saliva analysis in the clinical setting:
1000 revisiting an underused diagnostic tool. *Journal of investigative medicine*. 2002;50(3):214-25.
- 1001 33. Aljerf L, Alhaffar I. Salivary distinctiveness and modifications in males with diabetes and Behçet’s disease.
1002 *Biochemistry research international*. 2017;2017(1):9596202.
- 1003 34. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020
1004 statement: an updated guideline for reporting systematic reviews. *bmj*. 2021;372.
- 1005 35. Lynch S, Pfeiffer CM, Georgieff MK, Brittenham G, Fairweather-Tait S, Hurrell RF et al. Biomarkers of
1006 Nutrition for Development (BOND)—iron review. *The Journal of nutrition*. 2018;148:1001S-67S.
- 1007 36. Katona P, Katona-Apte J. The interaction between nutrition and infection. *Clinical Infectious Diseases*.
1008 2008;46(10):1582-8.
- 1009 37. Agarwal PK, Agarwal KN, Agarwal DK. Biochemical changes in saliva of malnourished children. *Am J Clin*
1010 *Nutr*. 1984 Feb;39(2):181-4.
- 1011 38. Franco-Martinez L, Tvarijonavičiute A, Martinez-Subiela S, Marquez G, Martinez Diaz N, Cugat R et al.
1012 Changes in lactate, ferritin, and uric acid in saliva after repeated explosive effort sequences. *The Journal of sports*
1013 *medicine and physical fitness*. 2019 Jun;59(6):902-9.
- 1014 39. Canatan D, Akdeniz SK. Iron and ferritin levels in saliva of patients with thalassemia and iron deficiency
1015 anemia. *Mediterranean journal of hematology and infectious diseases*. 2012;4(1):e2012051.
- 1016 40. Venkatesh Babu NS, Bhanushali PV. Evaluation and association of serum iron and ferritin levels in children
1017 with dental caries. *Journal of the Indian Society of Pedodontics and Preventive Dentistry*. 2017 Apr-Jun;35(2):106-9.
- 1018 41. Jagannathan N, Neelakantan P, Ramani P, Premkumar P, Natesan A, Sherlin HJ. Salivary ferritin—A concise
1019 update on current concepts. *Let the Science be your passion*. 2012.
- 1020 42. Canatan D, Akdeniz SK. Iron and ferritin levels in saliva of patients with thalassemia and iron deficiency
1021 anemia. *Mediterranean journal of hematology and infectious diseases*. 2012;4(1).
- 1022 43. Jagannathan N, Thiruvengadam C, Ramani P, Premkumar P, Natesan A, Sherlin H. Salivary ferritin as a
1023 predictive marker of iron deficiency anemia in children. *Journal of Clinical Pediatric Dentistry*. 2012;37(1):25-30.
- 1024 44. Alpdemir M, Eryilmaz M, Alpdemir MF, Topçu G, Azak A, Yücel D. Comparison of widely used
1025 biochemical analytes in the serum and saliva samples of dialysis patients. *Journal of medical biochemistry*.
1026 2018;37(3):346.
- 1027 45. Guo L-N, Yang Y-Z, Feng Y-Z. Serum and salivary ferritin and Hcpidin levels in patients with chronic
1028 periodontitis and type 2 diabetes mellitus. *BMC Oral Health*. 2018;18:1-9.
- 1029 46. Haji-Sattari F, Zarabadipour M, Hajmanoochehri F, Mirzadeh M. Salivary and Serum Ferritin Levels: Is
1030 There a Correlation? *Journal of Iranian Dental Association*. 2019;31(4):214-7.
- 1031 47. Rajkumaar J, Mathew MG. Association of severe early childhood caries with salivary ferritin. *Journal of*
1032 *Family Medicine and Primary Care*. 2020;9(8):3991-3.
- 1033 48. B LS, Rathnavelu V, Sabesan M, Ganesh A, Anandan S. A Study to Assess the Levels of Salivary Ferritin in
1034 Iron Deficiency Anemia Subjects and Healthy Subjects. *Cureus*. 2021 Aug;13(8):e17241.
- 1035 49. Rezazadeh F, Salehi S, Rezaee M. Salivary level of trace element in oral lichen planus, a premalignant
1036 condition. *Asian Pacific Journal of Cancer Prevention: APJCP*. 2019;20(7):2009.
- 1037 50. Costa EM, de Azevedo JAP, Martins RFM, Rodrigues VP, Alves CMC, Ribeiro CCC et al. Salivary iron
1038 (Fe) ion levels, serum markers of anemia and caries activity in pregnant women. *Revista Brasileira de Ginecologia e*
1039 *Obstetrícia/RBGO Gynecology and Obstetrics*. 2017;39(03):094-101.
- 1040 51. King JC, Brown KH, Gibson RS, Krebs NF, Lowe NM, Siekmann JH et al. Biomarkers of Nutrition for
1041 Development (BOND)—zinc review. *The Journal of nutrition*. 2016;146(4):858S-85S.
- 1042 52. Hotz C, Brown KH. Assessment of the risk of zinc deficiency in populations and options for its control. 2004.
- 1043 53. Wan Y, Zhang B. The impact of zinc and zinc homeostasis on the intestinal mucosal barrier and intestinal
1044 diseases. *Biomolecules*. 2022;12(7):900.
- 1045 54. Luca E, Crivoi F, Galeş C, Popescu E, Ciubotariu D, Nechifor M. Research on serum and saliva concentration
1046 of some bivalent cations in patient with suppurations of the oro-maxillo-facial area. *Revista Medico-chirurgicala a*
1047 *Societati de Medici si Naturalisti din Iasi*. 2009;113(3):899-903.

- 1048 55. Jayaram L, Chunilal S, Pickering S, Ruffin RE, Zalewski PD. Sputum zinc concentration and clinical
1049 outcome in older asthmatics. *Respirology*. 2011;16(3):459-66.
- 1050 56. De Carvalho FG, Rosa FT, Suen VMM, Freitas EC, Padovan GJ, Marchini JS. Evidence of zinc deficiency
1051 in competitive swimmers. *Nutrition*. 2012;28(11-12):1127-31.
- 1052 57. Marín Martínez L, Molino Pagán D, López Jornet P. Trace elements in saliva as markers of type 2 diabetes
1053 mellitus. *Biological trace element research*. 2018;186(2):354-60.
- 1054 58. Sharma A, Subramaniam P. Association of salivary zinc levels to dental caries and body mass index. A
1055 comparative study. *Journal of Clinical Pediatric Dentistry*. 2021;45(4):265-8.
- 1056 59. Aziz J, Vaithilingam RD, Radzi Z, Rahman MT. Inflammatory Responses in Periodontitis with or Without
1057 Rheumatoid Arthritis Alter Salivary Metallothionein and Zinc. *Biological Trace Element Research*.
1058 2023;201(7):3162-74.
- 1059 60. Hay D, Smith D, Schluckebier S, Moreno E. Relationship between concentration of human salivary statherin
1060 and inhibition of calcium phosphate precipitation in stimulated human parotid saliva. *Journal of Dental Research*.
1061 1984;63(6).
- 1062 61. Shannon IL, Feller R. Parotid saliva flow rate, calcium, phosphorus, and magnesium concentrations in
1063 relation to dental caries experience in children. *Pediatr Dent*. 1979;1(1):16-20.
- 1064 62. Logan D, Wallace S, Woodside J, McKenna G. The potential of salivary biomarkers of nutritional status and
1065 dietary intake: a systematic review. *Journal of Dentistry*. 2021;115:103840.
- 1066 63. Pannunzio E, Amancio OMS, Vitale MSdS, Souza DNd, Mendes FM, Nicolau J. Analysis of the stimulated
1067 whole saliva in overweight and obese school children. *Revista da Associação Médica Brasileira*. 2010;56:32-6.
- 1068 64. Mattioli TMF, Koubik AC, de Oliveira Ribas M, França BHS, Brancher JA, de Lima AAS. Salivary flow
1069 rate, calcium, urea, total protein, and amylase levels in fanconi anemia. *Journal of Pediatric Hematology/Oncology*.
1070 2010;32(2):e46-e9.
- 1071 65. Kumbhojkar SV, Kale AD, Kumbhojkar VR, Desai KM. Salivary calcium as a diagnostic tool for screening
1072 of osteoporosis in postmenopausal women. *Journal of Oral and Maxillofacial Pathology*. 2019;23(2):192-7.
- 1073 66. Pratyusha N, Vinay C, Uloopi K, RojaRamya KS, Ahalya P, Devi C. Association of serum Vitamin D and
1074 salivary calcium and phosphorus levels in 3-11-year-old schoolchildren with dental caries. *Journal of Indian Society
1075 of Pedodontics and Preventive Dentistry*. 2021;39(3):240-5.
- 1076 67. Çevik-Aras H, Musa S, Olofsson R, Almståhl A, Almhöjd U. Patients with oral lichen planus display lower
1077 levels of salivary acidic glycoproteins than individuals without oral mucosal disease. *Clinical Oral Investigations*.
1078 2023;28(1):2.
- 1079 68. Johansson I, Lenander-Lumikari M, Saellström A-K. Saliva composition in Indian children with chronic
1080 protein-energy malnutrition. *Journal of dental research*. 1994;73(1):11-9.
- 1081 69. Tanumihardjo SA, Russell RM, Stephensen CB, Gannon BM, Craft NE, Haskell MJ et al. Biomarkers of
1082 Nutrition for Development (BOND)—vitamin A review. *The Journal of nutrition*. 2016;146(9):1816S-48S.
- 1083 70. Gilbert C. What is vitamin A and why do we need it? *Community Eye Health*. 2013;26(84):65.
- 1084 71. Maad AH, Aljerf L, Aljerf A, Dayoob CR, Sukkar AJ, Alajlani M. A cross-sectional study on demographic
1085 characteristics, nutritional knowledge, and supplement use patterns. *International Journal of Kinesiology & Sports
1086 Science*. 2024;12(4):21.
- 1087 72. Rezazadeh F, Abedi F, Ranjbar Z, Khorami ET, Tabesh A. Evaluating the Salivary Levels of Vitamins A,
1088 B12, C, D3, E in Oral Lichen Planus Patients in Southwest of Iran. 2023.
- 1089 73. Blakeley M, Sobczyńska-Malefora A, Carpenter G. The origins of salivary vitamin a, vitamin B12 and
1090 vitamin D-binding proteins. *Nutrients*. 2020;12(12):3838.
- 1091 74. Lee JY, So T-Y, Thackray J. A review on vitamin d deficiency treatment in pediatric patients. *The Journal
1092 of Pediatric Pharmacology and Therapeutics*. 2013;18(4):277-91.
- 1093 75. Rebelos E, Tentolouris N, Jude E. The role of vitamin D in health and disease: a narrative review on the
1094 mechanisms linking vitamin D with disease and the effects of supplementation. *Drugs*. 2023;83(8):665-85.
- 1095 76. Park JE, Pichiah PT, Cha Y-S. Vitamin D and metabolic diseases: growing roles of vitamin D. *Journal of
1096 obesity & metabolic syndrome*. 2018;27(4):223.
- 1097 77. Aljerf L, Aljerf N. Food products quality and nutrition in relation to public. Balancing health and disease.
1098 *Prog Nutr*. 2023;25(1):10-23751.
- 1099 78. Giustina A, Bilezikian JP, Adler RA, Banfi G, Bikle DD, Binkley NC et al. Consensus statement on vitamin
1100 D status assessment and supplementation: whys, whens, and hows. *Endocrine reviews*. 2024;45(5):625-54.

- 1101 79. Bahramian A, Falsafi P, Abbasi T, Ghanizadeh M, Abedini M, Kavooosi F et al. Comparing serum and salivary
 1102 levels of vitamin D in patients with recurrent aphthous stomatitis and healthy individuals. *Journal of Dentistry*.
 1103 2018;19(4):295.
- 1104 80. Costantini E, Sinjari B, Piscopo F, Porreca A, Reale M, Caputi S et al. Evaluation of salivary cytokines and
 1105 vitamin D levels in periodontopathic patients. *International journal of molecular sciences*. 2020;21(8):2669.
- 1106 81. Pruszkowska-Przybylska P, Sitek A, Rosset I, Sobalska-Kwapis M, Słomka M, Strapagiel D et al.
 1107 Association of saliva 25 (OH) D concentration with body composition and proportion among pre-pubertal and pubertal
 1108 Polish children. *American Journal of Human Biology*. 2020;32(5):e23397.
- 1109 82. Araujo DS, de Oliveira Scudine KG, Pedroni-Pereira A, Gavião MBD, Pereira EC, Fonseca FLA et al.
 1110 Salivary uric acid is a predictive marker of body fat percentage in adolescents. *Nutrition research*. 2020;74:62-70.
- 1111 83. Usman M, Woloshynowych M, Britto JC, Bilkevic I, Glassar B, Chapman S et al. Obesity, oxidative DNA
 1112 damage and vitamin D as predictors of genomic instability in children and adolescents. *International Journal of*
 1113 *Obesity*. 2021;45(9):2095-107.
- 1114 84. Samanta I, Patil DJ, More CB. Assessment of vitamin D levels in patients with oral potentially malignant
 1115 disorders and oral squamous cell carcinoma-A cross-sectional study. *Journal of Oral Biology and Craniofacial*
 1116 *Research*. 2024;14(1):27-32.
- 1117 85. Gholizadeh N, Pirezadeh F, Mirzaii-Dizgah I, Sheykhbahaei N. Relationship between salivary vitamin D
 1118 deficiency and oral lichen planus. *Photodermatology, Photoimmunology & Photomedicine*. 2020;36(5):384-6.
- 1119 86. Allen LH, Miller JW, De Groot L, Rosenberg IH, Smith AD, Refsum H et al. Biomarkers of Nutrition for
 1120 Development (BOND): vitamin B-12 review. *The Journal of nutrition*. 2018;148:1995S-2027S.
- 1121 87. Rizzo G, Laganà AS. A review of vitamin B12. *Molecular nutrition*. 2020:105-29.
- 1122 88. Al-hamdani GM, Yas LS. Serum and Salivary Vitamin B12 Levels among Iron Deficiency Anemia Patient
 1123 with Recurrent Aphthous Stomatitis: An Analytical Cross-Sectional Study. *Dental Hypotheses*. 2023;14(2):55-8.
- 1124 89. Bailey LB, Stover PJ, McNulty H, Fenech MF, Gregory III JF, Mills JL et al. Biomarkers of nutrition for
 1125 development—folate review. *The Journal of nutrition*. 2015;145(7):1636S-80S.
- 1126 90. Rai B, Kaur J, Jacobs R, Singh J. Possible action mechanism for curcumin in pre-cancerous lesions based on
 1127 serum and salivary markers of oxidative stress. *Journal of oral science*. 2010;52(2):251-6.
- 1128 91. Thurnham DI. Interactions between nutrition and immune function: using inflammation biomarkers to
 1129 interpret micronutrient status. *Proceedings of the Nutrition Society*. 2014;73(1):1-8.
- 1130 92. Mei Z, Namaste SM, Serdula M, Suchdev PS, Rohner F, Flores-Ayala R et al. Adjusting total body iron for
 1131 inflammation: Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project. *The*
 1132 *American journal of clinical nutrition*. 2017;106:383S-9S.
- 1133 93. Tuuminen T, Sorsa M, Tornudd M, Poussa T, Antila E, Jaakkola K. The association between high sensitivity
 1134 C-reactive protein and micronutrient levels: A cross-sectional analysis based on a laboratory database. *Clinical*
 1135 *Nutrition ESPEN*. 2019;33:283-9.
- 1136 94. Pesqueda-Cendejas K, Parra-Rojas I, Mora-García PE, Montoya-Buelna M, Ruiz-Ballesteros AI, Meza-Meza
 1137 MR et al. CRP serum levels are associated with high cardiometabolic risk and clinical disease activity in systemic
 1138 lupus erythematosus patients. *Journal of Clinical Medicine*. 2022;11(7):1849.
- 1139 95. Naidoo T, Konkol K, Biccard B, McKune A, Dubose K. Elevated salivary C-reactive protein predicted by
 1140 low cardio-respiratory fitness and being overweight in African children: cardiovascular topic. *Cardiovascular Journal*
 1141 *of Africa*. 2012;23(9):501-6.
- 1142 96. Ebersole JL, Kryscio RJ, Campbell C, Kinane D, McDevitt J, Christodoulides N et al. Salivary and serum
 1143 adiponectin and C-reactive protein levels in acute myocardial infarction related to body mass index and oral health.
 1144 *Journal of periodontal research*. 2017;52(3):419-27.
- 1145 97. Selvaraju V, Babu JR, Geetha T. Association of salivary C-reactive protein with the obesity measures and
 1146 markers in children. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2019:1239-47.
- 1147 98. Wetterö J, von Löhneysen S, Cobar F, Kristenson M, Garvin P, Sjöwall C. Pronounced diurnal pattern of
 1148 salivary C-reactive protein (CRP) with modest associations to circulating CRP levels. *Frontiers in immunology*.
 1149 2021;11:607166.
- 1150 99. Agho ET, Owotade FJ, Kolawole BA, Oyetola EO, Adedeji TA. Salivary inflammatory biomarkers and
 1151 glycated haemoglobin among patients with type 2 diabetic mellitus. *BMC Oral Health*. 2021;21:1-8.
- 1152 100. Alqaderi H, Hegazi F, Al-Mulla F, Chiu C-J, Kantarci A, Al-Ozairi E et al. Salivary biomarkers as predictors
 1153 of obesity and intermediate hyperglycemia in adolescents. *Frontiers in Public Health*. 2022;10:800373.

- 1154 101. Bizjak DA, Ammerpohl O, Schulz SV, Wendt J, Steinacker JM, Flechtner-Mors M. Pro-inflammatory and
 1155 (Epi-) genetic markers in saliva for disease risk in childhood obesity. *Nutrition, Metabolism and Cardiovascular*
 1156 *Diseases*. 2022;32(6):1502-10.
- 1157 102. Bachtiar E, Bachtiar BM, Kusumaningrum A, Sunarto H, Soeroro Y, Sulijaya B et al. The utility of salivary
 1158 CRP and IL-6 as a non-invasive measurement evaluated in patients with COVID-19 with and without diabetes.
 1159 *F1000Research*. 2024;12:419.
- 1160 103. Luo Z, Lei H, Sun Y, Liu X, Su D-F. Orosomucoid, an acute response protein with multiple modulating
 1161 activities. *Journal of physiology and biochemistry*. 2015;71:329-40.
- 1162 104. Luo H, Geng J, Zeiler M, Nieckula E, Sandalinas F, Williams A et al. A practical guide to adjust micronutrient
 1163 biomarkers for inflammation using the BRINDA method. *The Journal of nutrition*. 2023;153(4):1265-72.
- 1164 105. Gannon BM, Glesby MJ, Finkelstein JL, Raj T, Erickson D, Mehta S. A point-of-care assay for alpha-1-acid
 1165 glycoprotein as a diagnostic tool for rapid, mobile-based determination of inflammation. *Current research in*
 1166 *biotechnology*. 2019;1:41-8.
- 1167 106. Rauf A, Shariati MA, Khalil AA, Bawazeer S, Heydari M, Plygun S et al. Hepcidin, an overview of
 1168 biochemical and clinical properties. *Steroids*. 2020;160:108661.
- 1169 107. Ganz T, Nemeth E. Hepcidin and iron homeostasis. *Biochimica et Biophysica Acta (BBA)-Molecular Cell*
 1170 *Research*. 2012;1823(9):1434-43.
- 1171 108. Arnold J, Sangwaiya A, Manglam V, Geoghegan F, Thursz M, Busbridge M. Presence of hepcidin-25 in
 1172 biological fluids: bile, ascitic and pleural fluids. *World journal of gastroenterology: WJG*. 2010;16(17):2129.
- 1173 109. Dewan P, Dixit A, Gomber S, Kotru M, Banerjee BD, Tyagi V et al. Serum and urinary hepcidin for
 1174 diagnosing iron-deficiency anemia in under-5 children. *Journal of pediatric hematology/oncology*. 2019;41(4):e216-
 1175 e20.
- 1176 110. Busbridge M, Griffiths C, Ashby D, Gale D, Jayantha A, Sanwaiya A et al. Development of a novel
 1177 immunoassay for the iron regulatory peptide hepcidin. *British journal of biomedical science*. 2009;66(3):150-7.
- 1178 111. Hansen IS, Baeten DL, den Dunnen J. The inflammatory function of human IgA. *Cellular and molecular life*
 1179 *sciences*. 2019;76(6):1041-55.
- 1180 112. Huus KE, Petersen C, Finlay BB. Diversity and dynamism of IgA- microbiota interactions. *Nature Reviews*
 1181 *Immunology*. 2021;21(8):514-25.
- 1182 113. Abu Jamra SR, Komatsu CG, Barbosa Jr F, Roxo-Junior P, Navarro AM. Proposal to screen for zinc and
 1183 selenium in patients with IgA deficiency. *Nutrients*. 2023;15(9):2145.
- 1184 114. Patel A, Jialal I. Biochemistry, immunoglobulin A. StatPearls [Internet]: StatPearls Publishing; 2023.
- 1185 115. Miller EM, McConnell DS. Brief communication: chronic undernutrition is associated with higher mucosal
 1186 antibody levels among Ariaal infants of northern Kenya. *American journal of physical anthropology*.
 1187 2012;149(1):136-41.
- 1188 116. Fadel HT, Pliaki A, Gronowitz E, Mårild S, Ramberg P, Dahlèn G et al. Clinical and biological indicators of
 1189 dental caries and periodontal disease in adolescents with or without obesity. *Clinical oral investigations*. 2014;18:359-
 1190 68.
- 1191 117. Perez MM, Pessoa JS, Ciamponi AL, Diniz MB, Santos MTBR, Alves HHdO et al. Correlation of salivary
 1192 immunoglobulin A with Body Mass Index and fat percentage in overweight/obese children. *Journal of applied oral*
 1193 *science*. 2018;27:e20180088.
- 1194 118. Schlesinger L, Arevalo M, Arredondo S, Diaz M, Lönnerdal B, Stekel A. Effect of a zinc-fortified formula
 1195 on immunocompetence and growth of malnourished infants. *The American journal of clinical nutrition*.
 1196 1992;56(3):491-8.
- 1197 119. de Souza DC, Matos VA, Dos Santos VO, Medeiros IF, Marinho CS, Nascimento PR et al. Effects of high-
 1198 intensity interval and moderate-intensity continuous exercise on inflammatory, leptin, IgA, and lipid peroxidation
 1199 responses in obese males. *Frontiers in physiology*. 2018;9:567.
- 1200 120. van Heerden C, Oosthuizen, R., van Wyk, Prinsloo, P., Anderson R. Evaluation of neutrophil and lymphocyte
 1201 function in subjects with iron deficiency. *South African Medical Journal*. 1981;59(4):111-3.
- 1202 121. Cripps A, Otczyk DC, Barker J, Lehmann D, Alpers MP. The relationship between undernutrition and
 1203 humoral immune status in children with pneumonia in Papua New Guinea. *Papua New Guinea Medical Journal*.
 1204 2008;51(3/4):120-30.
- 1205 122. Surono IS, Koestomo FP, Novitasari N, Zakaria FR. Novel probiotic *Enterococcus faecium* IS-27526
 1206 supplementation increased total salivary sIgA level and bodyweight of pre-school children: a pilot study. *Anaerobe*.
 1207 2011;17(6):496-500.

- 1208 123. Vulevic J, Juric A, Tzortzis G, Gibson GR. A mixture of trans-galactooligosaccharides reduces markers of
1209 metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. *The Journal of*
1210 *nutrition*. 2013;143(3):324-31.
- 1211 124. Solé D ZM, Leser PG, et al. Levels of IgA in saliva of normal and atopic individuals, determined by secretory
1212 anti-IgA antibodies and serum antigen. *Rev Bras Alerg Immunol*. 1987;10:120-5.
- 1213 125. Silva LB, dos Santos Neto AP, Maia SM, dos Santos Guimarães C, Quidute IL, Carvalho AdA et al. The role
1214 of TNF- α as a proinflammatory cytokine in pathological processes. *The Open Dentistry Journal*. 2019;13(1).
- 1215 126. Popa C, Netea MG, Van Riel PL, Van Der Meer JW, Stalenhoef AF. The role of TNF- α in chronic
1216 inflammatory conditions, intermediary metabolism, and cardiovascular risk. *Journal of lipid research*.
1217 2007;48(4):751-62.
- 1218 127. Jang D-i, Lee A-H, Shin H-Y, Song H-R, Park J-H, Kang T-B et al. The role of tumor necrosis factor alpha
1219 (TNF- α) in autoimmune disease and current TNF- α inhibitors in therapeutics. *International journal of molecular*
1220 *sciences*. 2021;22(5):2719.
- 1221 128. Valaperti A, Li Z, Vonow-Eisenring M, Probst-Müller E. Diagnostic methods for the measurement of human
1222 TNF-alpha in clinical laboratory. *Journal of pharmaceutical and biomedical analysis*. 2020;179:113010.
- 1223 129. Berkhout LC, l'Ami MJ, Ruwaard J, Hart MH, Heer PO-d, Bloem K et al. Dynamics of circulating TNF
1224 during adalimumab treatment using a drug-tolerant TNF assay. *Science translational medicine*.
1225 2019;11(477):eaat3356.
- 1226 130. Martínez-Lozano N, Tvarijonavičiute A, Ríos R, Barón I, Scheer FA, Garaulet M. Late eating is associated
1227 with obesity, inflammatory markers and circadian-related disturbances in school-aged children. *Nutrients*.
1228 2020;12(9):2881.
- 1229 131. Soto-Méndez MJ, Romero-Abal ME, Aguilera CM, Rico MC, Solomons NW, Schümann K et al.
1230 Associations among inflammatory biomarkers in the circulating, plasmatic, salivary and intraluminal anatomical
1231 compartments in apparently healthy preschool children from the western highlands of Guatemala. *PLoS One*.
1232 2015;10(6):e0129158.
- 1233 132. de Vargas LdS, Jantsch J, Fontoura JR, Dorneles GP, Peres A, Guedes RP. Effects of zinc supplementation
1234 on inflammatory and cognitive parameters in middle-aged women with overweight or obesity. *Nutrients*.
1235 2023;15(20):4396.
- 1236 133. Alasqah MN. Influence of adjunctive non-surgical peri-implant therapy on clinical and salivary cytokine
1237 profile in obese patients. *Photodiagnosis and Photodynamic Therapy*. 2022;37:102721.
- 1238 134. Alkan B, Guzeldemir-Akcakanat E. Evaluation of adipokine levels in obese women with periodontitis: A
1239 cohort study. *American Journal of Dentistry*. 2021;34(5):267-72.
- 1240 135. Attlee A, Hasan H, AlQattan A, Sarhan N, Alshammari R, Ali S et al. Relationship of salivary
1241 adipocytokines, diet quality, physical activity, and nutrition status in adult Emirati females in United Arab Emirates.
1242 *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2019;13(1):40-6.
- 1243 136. Syrjäläinen S, GURSOY UK, GURSOY M, Pussinen P, Pietiäinen M, Jula A et al. Salivary cytokine biomarker
1244 concentrations in relation to obesity and periodontitis. *Journal of clinical medicine*. 2019;8(12):2152.
- 1245 137. Foratori-Junior GA, Mosquim V, Buzalaf MAR, de Carvalho Sales-Peres SH. Salivary cytokines levels,
1246 maternal periodontitis and infants' weight at birth: A cohort study in pregnant women with obesity. *Placenta*.
1247 2021;115:151-7.
- 1248 138. Lehmann-Kalata A, Miechowicz I, Korybalska K, Swora-Cwynar E, Czepulis N, Łuczak J et al. Salivary
1249 fingerprint of simple obesity. *Cytokine*. 2018;110:174-80.
- 1250 139. Ostrowska L, Gornowicz A, Pietraszewska B, Bielawski K, Bielawska A. Which salivary components can
1251 differentiate metabolic obesity? *PloS one*. 2020;15(6):e0235358.
- 1252 140. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. *Cold Spring Harbor*
1253 *perspectives in biology*. 2014;6(10):a016295.
- 1254 141. Covarrubias AJ, Horng T. IL-6 strikes a balance in metabolic inflammation. *Cell metabolism*.
1255 2014;19(6):898-9.
- 1256 142. McElvaney OJ, Curley GF, Rose-John S, McElvaney NG. Interleukin-6: obstacles to targeting a complex
1257 cytokine in critical illness. *The Lancet Respiratory Medicine*. 2021;9(6):643-54.
- 1258 143. Cioffi I, Scialò F, Di Vincenzo O, Gelzo M, Marra M, Testa A et al. Serum interleukin 6, controlling
1259 nutritional status (CONUT) score and phase angle in patients with Crohn's disease. *Nutrients*. 2023;15(8):1953.
- 1260 144. Doğan GE, Toraman A, Şebin SÖ, Doğan Ç, Güngör A, Aksoy H et al. Salivary IL-6 and IL-10 levels in
1261 subjects with obesity and gingivitis. *American Journal of Dentistry*. 2016;29(5):261-5.

- 1262 145. Pırsean C, Neguț C, Stefan-van Staden R-I, Dinu-Pirvu CE, Armean P, Udeanu DI. The salivary levels of
1263 leptin and interleukin-6 as potential inflammatory markers in children obesity. *PLoS One*. 2019;14(1):e0210288.
- 1264 146. Deng Q, Wong HM, Peng S. Alterations in salivary biomarkers in relation to periodontal health and obesity
1265 among Hong Kong adolescents. *Journal of Dentistry*. 2024;146:105055.
- 1266 147. Potempa-Jeziorowska M, Jonczyk P, Świętochowska E, Kucharzewski M. Analysis of ghrelin, leptin, and
1267 interleukin-6 salivary concentration among children aged 7–10 years and its relationship with nutritional status and
1268 some anthropometric data. *Pediatric Endocrinology Diabetes and Metabolism*. 2022;28(4):263-73.
- 1269 148. Baskaradoss JK, Tavares M, Al-Mulla F, Al-Ozairi E, Abu-Farha M, Bin-Hasan S et al. Association between
1270 frequency of Toothbrushing and metabolic syndrome among adolescents: a 5-Year Follow-Up study. *International
1271 journal of environmental research and public health*. 2022;19(1):508.
- 1272 149. Ostrowska L, Smarkusz-Zarzecka J, Gornowicz A, Lenzion K, Zyśk B, Pogodziński D. Analysis of selected
1273 salivary adipokines and cytokines in patients with obesity—A pilot study. *International Journal of Molecular
1274 Sciences*. 2023;24(4):4145.
- 1275 150. Abduljabbar T, Al-Sahaly F, Kellesarian SV, Kellesarian TV, Al-Anazi M, Al-Khathami M et al. Comparison
1276 of peri-implant clinical and radiographic inflammatory parameters and whole salivary destructive inflammatory
1277 cytokine profile among obese and non-obese men. *Cytokine*. 2016;88:51-6.
- 1278 151. Safabakhsh D, Jazaeri M, Abdolsamadi H, Abassi E, Farhadian M. Comparison of salivary interleukin-6,
1279 interleukin-8, C-reactive protein levels and total antioxidants capacity of obese individuals with normal-weight ones.
1280 *Romanian journal of internal medicine= Revue roumaine de medecine interne*. 2022;60(4):215-21.
- 1281 152. Zyśk B, Ostrowska L, Smarkusz-Zarzecka J, Witczak-Sawczuk K, Gornowicz A, Bielawska A. Pro-
1282 inflammatory adipokine and cytokine profiles in the saliva of obese patients with non-alcoholic fatty liver disease
1283 (NAFLD)—a pilot study. *International journal of molecular sciences*. 2023;24(3):2891.
- 1284 153. Acevedo S, M. Andrade J. Effects of a spice-blended honey muffin on salivary inflammation markers in
1285 adults with obesity: a feasibility trial. *Annals of Medicine*. 2023;55(2):2245325.
- 1286 154. Al-Hamoudi N, Abduljabbar T, Mirza S, Al-Sowygh ZH, Vohra F, Javed F et al. Non-surgical periodontal
1287 therapy reduces salivary adipocytokines in chronic periodontitis patients with and without obesity. *Journal of
1288 investigative and clinical dentistry*. 2018;9(2):e12314.
- 1289 155. Li Y, Ou Y, Fan K, Liu G. Salivary diagnostics: opportunities and challenges. *Theranostics*.
1290 2024;14(18):6969.
- 1291 156. Kashyap B, Kullaa A. Salivary metabolites produced by oral microbes in oral diseases and oral squamous
1292 cell carcinoma: a review. *Metabolites*. 2024;14(5):277.
- 1293 157. Kaczor-Urbanowicz KE, Martin Carreras-Presas C, Aro K, Tu M, Garcia-Godoy F, Wong DT. Saliva
1294 diagnostics—Current views and directions. *Experimental Biology and Medicine*. 2017;242(5):459-72.
- 1295 158. Ebersole JL, Hasturk H, Huber M, Gellibolian R, Markaryan A, Zhang XD et al. Realizing the clinical utility
1296 of saliva for monitoring oral diseases. *Periodontology 2000*. 2024;95(1):203-19.
- 1297 159. Spielmann N, Wong DT. Saliva: diagnostics and therapeutic perspectives. *Oral diseases*. 2011;17(4):345-
1298 54.
- 1299 160. Hofman LF. Human saliva as a diagnostic specimen. *The Journal of nutrition*. 2001;131(5):1621S-5S.
- 1300 161. Koh DS-Q, Koh GC-H. The use of salivary biomarkers in occupational and environmental medicine.
1301 *Occupational and environmental medicine*. 2007;64(3):202-10.
- 1302 162. Xu S, Mumuni AN, Tuason RTS, Maki KA. Methodological considerations in saliva-based biomarker
1303 research: Addressing patient-specific variability in translational research protocols. *Current Protocols*.
1304 2025;5(10):e70235.
- 1305 163. Granger DA, Johnson SB, Szanton SL, Out D, Schumann LL. Incorporating salivary biomarkers into nursing
1306 research: an overview and review of best practices. *Biological research for nursing*. 2012;14(4):347-56.
- 1307 164. Mortazavi H, Yousefi-Koma A-A, Yousefi-Koma H. Extensive comparison of salivary collection,
1308 transportation, preparation, and storage methods: a systematic review. *BMC Oral Health*. 2024;24(1):168.
- 1309 165. Fey JM, Bikker FJ, Hesse D. Saliva collection methods among children and adolescents: a scoping review.
1310 *Molecular Diagnosis & Therapy*. 2024;28(1):15-26.
- 1311 166. Martínez AD, Ruelas L, Granger DA. Household fear of deportation in Mexican-origin families: Relation to
1312 body mass index percentiles and salivary uric acid. *American journal of human biology*. 2017;29(6):e23044.
- 1313 167. Khurshid Z, Zohaib S, Najeeb S, Zafar MS, Slowey PD, Almas K. Human saliva collection devices for
1314 proteomics: an update. *International journal of molecular sciences*. 2016;17(6):846.

- 1315 168. Henson BS, Wong DT. Collection, storage, and processing of saliva samples for downstream molecular
1316 applications. *Oral biology: molecular techniques and applications*: Springer; 2010. p. 21-30.
- 1317 169. Barranco T, P Rubio C, Tvarijonavičiute A, Rubio M, Damia E, Lamy E et al. Changes of salivary biomarkers
1318 under different storage conditions: effects of temperature and length of storage. *Biochemia medica*. 2019;29(1):94-
1319 111.
- 1320 170. Kivlighan KT, Granger DA, Schwartz EB, Nelson V, Curran M, Shirtcliff EA. Quantifying blood leakage
1321 into the oral mucosa and its effects on the measurement of cortisol, dehydroepiandrosterone, and testosterone in saliva.
1322 *Hormones and behavior*. 2004;46(1):39-46.
- 1323 171. Kivlighan KT, Granger DA, Schwartz EB. Blood contamination and the measurement of salivary
1324 progesterone and estradiol. *Hormones and Behavior*. 2005;47(3):367-70.
- 1325 172. Padilla GA, Calvi JL, Taylor MK, Granger DA. Saliva collection, handling, transport, and storage: Special
1326 considerations and best practices for interdisciplinary salivary bioscience research. *Salivary bioscience: Foundations
1327 of interdisciplinary saliva research and applications*. 2020:21-47.
- 1328 173. Nonzee V, Manopatanakul S, Khovidhunkit S-oP. Xerostomia, hyposalivation and oral microbiota in patients
1329 using antihypertensive medications. *Journal of the Medical Association of Thailand*. 2012;95(1):96.
- 1330 174. Dodds MW, Yeh CK, Johnson DA. Salivary alterations in type 2 (non-insulin-dependent) diabetes mellitus
1331 and hypertension. *Community dentistry and oral epidemiology*. 2000;28(5):373-81.
- 1332 175. von Bültzingslöwen I, Sollecito TP, Fox PC, Daniels T, Jonsson R, Lockhart PB et al. Salivary dysfunction
1333 associated with systemic diseases: systematic review and clinical management recommendations. *Oral Surgery, Oral
1334 Medicine, Oral Pathology, Oral Radiology, and Endodontology*. 2007;103:S57. e1-S. e15.
- 1335

1336

Tables

Table 1. Number of articles for each biomarker

Salivary Biomarkers	Number of Studies
Minerals	
Iron	5
Ferritin	7
sTfR	0
Zinc	7
Selenium	0
Calcium	6
Vitamins	
Vitamin A	2
Vitamin B12	4
Folic acid	1
Vitamin C	2
Vitamin D	9
Vitamin E	2
Inflammatory biomarkers	
AGP	1
CRP	9
Hepcidin	2
IgA	11
Cytokines	27
- TNF- α	11
- IL-6	18
- Other cytokines	22

1338 **Table 2.** Summary of studies with salivary ferritin and results

(a) Country (b) Settings (c) Design	Study participants with sample size	Age of the participants	Salivary levels of ferritin (Mean \pm SD)	Serum levels of ferritin (Mean \pm SD)	Correlation coefficient between serum and salivary levels of ferritin	Reference
(a) Turkey (b) University hospital (c) Cross-sectional study	(a) patients with Transfusion-dependent β -thalassemia major (n = 71) (b) patients with thalassemia intermedia (n = 10) (c) patients with thalassemia trait (n = 15) (d) patients with IDA (n = 30) (e) age- and sex-matched healthy controls (n = 34)	(a) 6-23 (11.6 \pm 4.45) years (b) 6-25 (12.4 \pm 6.0) years (c) 15-18 (16.0 \pm 1.9) years (d) 7-14 (9.1 \pm 2.12) years (e) 7-15 (10 \pm 2.22) years	(a) Transfusion-dependent β -thalassemia major: 2529.6 \pm 1081.3 ng/dl (b) thalassemia intermedia: 1166.0 \pm 951.3 ng/dl (c) thalassemia trait: 112.2 \pm 145.9 ng/dl (d) IDA: 18.6 \pm 8.53 ng/dl (e) healthy controls: 42.5 \pm 42.25 ng/dl	(a) thalassemia major: 2826.35 \pm 1711 ng/dl (b) thalassemia intermedia: 1492.1 \pm 1445.1 ng/dl (c) thalassemia trait: 126 \pm 150 ng/dl (d) IDA: 6.7 \pm 3.49 ng/dl (e) healthy controls: 29.67 \pm 16.78 ng/dl	(a) thalassemia major: r =0.364 (p=0.034) (b) thalassemia intermedia: rho =0.891 (p=0.001) (c) thalassemia trait: rho =0.831 (p<0.001) (d) IDA: r =0.880 (p<0.001) (e) healthy controls: r =0.842 (p<0.001)	Canatan et al. 2012
(a) India (b) Dental college	(a) patients with IDA (n = 30)	8-14 years	(a) patients with IDA: 153.24 \pm 23.58 ng/dl	(a) patients with IDA: 31.69 \pm 6.28 ng/dl	Not done	Jagannathan et al. 2012

(c) case-control study	(b) healthy controls (n = 30)		(b) healthy controls: 93.87 ± 26.15 ng/dl	(b) healthy controls: 90.45 ± 8.23 ng/dl		
(a) Turkey (b) Hospital (c) Cross-sectional study	(a) healthy control (n = 40) (b) peritoneal dialysis (n = 44) (c) hemodialysis patients (n = 44)	(a) 43.9±8.5 years (b) 45.8 ±13.3 years (c) 48.2±12.3 years	(a) healthy controls: 27.5 ± 52.9 ng/mL (b) peritoneal dialysis: 10.8 ± 7.57 ng/mL (c) before hemodialysis : 34.9 ± 22.2 ng/mL (d) after hemodialysis : 61.1 ± 58.0 ng/mL	(a) healthy controls: 55.5 ± 55.9 ng/mL (b) peritoneal dialysis: 501 ± 192 ng/mL (c) before hemodialysis: 869 ± 1070 ng/mL (d) after hemodialysis: 1255 ± 612 ng/mL	(a) healthy controls: r = 0.55 (p<0.001) (b) peritoneal dialysis: not reported (c) before hemodialysis: not reported (d) after hemodialysis: not reported	Alpdemir et al. 2018
(a) China (b) University hospital (c) Cross-sectional study	(a) participants with T2DM (n = 22) (b) participants with CP (n = 22) (c) participants with both CP and T2DM (n = 22) (d) healthy controls (n = 22)	(a) 56.45 ± 11.80 years (b) 58.09 ± 9.97 years (c) 62.82 ± 10.72 years (d) 52.45 ± 10.01 years	(a) T2DM: 12.61 ± 6.4 ng/mL (b) CP: 16.74 ± 11.5 ng/mL (c) CP + T2DM: 12.81 ± 7.9 ng/mL (d) healthy controls: 6.50 ± 3.0 ng/mL	(a) T2DM: 196.3 ± 208.0 ng/mL (b) CP: 265.1 ± 142.5 ng/mL (c) CP + T2DM: 197.7 ± 176.1 ng/mL (d) healthy controls: 196.2 ± 100.0 ng/mL	Overall: R ² = 0.064 (p = 0.017)	Guo et al. 2018
(a) Iran (b) Clinic/medical laboratory	Volunteers with no obvious systemic disorders	35.2±11.4 years	Not reported	Not reported	rho=0.27 (p = 0.004)	Haji-Sattari et al. 2019

(c) cross-sectional study	and no history of smoking or medication intake (n =107)					
(a) India (b) Dental College (c) Case-control study	(a) children with caries (n = 60) (b) age- and sex-matched controls (n = 60)	(a) 4.2 ± 0.9 years (b) 4.1 ± 0.7 years	(a) children with caries: 1595.30±186 (b) controls: 921.60±129.10 ng/mL	Not done	Not done	Rajkumar et al. 2020
(a) India (b) Hospital (c) Comparative study	(a) female patients with IDA (n = 15) (b) non-anemic female control (n = 15)	(a) 36.26±7.28 years (b) 31.32±3.51 years	(a) female patients with IDA: 1393.70±479.00 ng/mL (b) non-anemic female controls: 941.80±629.00 ng/mL	(a) female patients with IDA: 3.63±2.31 ng/mL (b) non-anemic female controls: 45.65±7.97 ng/mL	Not done	Lokesh Sundaram B et al. 2021

1339 SD, standard deviation; IDA, iron deficiency anemia; CP, chronic periodontitis; T2DM, type 2

1340 diabetes mellitus.

1341

1342 **Table 3.** Summary of studies with salivary iron and results

(a) Country (b) Settings (c) Design	Study participants with sample size	Age of the participants	Salivary levels of iron (Mean \pm SD)	Serum levels of iron (Mean \pm SD)	Correlation coefficient between serum and salivary levels of iron	Reference
(a) Turkey (b) University hospital (c) Cross-sectional study	(a) patients with Transfusion-dependent β -thalassemia major (n = 71) (b) patients with thalassemia intermedia (n = 10) (c) patients with thalassemia trait (n = 15) (d) patients with IDA (n = 30) (e) age- and sex-matched healthy controls (n = 34)	(a) 6-23 (11.6 \pm 4.45) years (b) 6-25 (12.4 \pm 6.0) years (c) 15-18 (16.0 \pm 1.9) years (d) 7-14 (9.1 \pm 2.12) years (e) 7-15 (10 \pm 2.22) years	a) Transfusion-dependent β -thalassemia major: 253.64 \pm 91.0 mg/dL (b) thalassemia intermedia: 150.1 \pm 61.1 mg/dL (c) thalassemia trait: 101.1 \pm 41.16 mg/dL (d) IDA: 24.6 \pm 10.0 mg/dL (e) healthy controls: 74.20 \pm 40.7 mg/dL	(a) thalassemia major: 192.25 \pm 76.87 mg/dL (b) thalassemia intermedia: 132.20 \pm 55.7 mg/dL (c) thalassemia trait: 93.40 \pm 39.14 mg/dL (d) IDA: 13.80 \pm 24.70 mg/dL (e) healthy controls: 62.37 \pm 33.0 mg/dL	(a) thalassemia major: r =0.972, p<0.001 (b) thalassemia intermedia: rho =0.720, p=0.019 (c) thalassemia trait: rho =0.955, p<0.001 (d) IDA: r =0.368, p=0.045 (e) healthy controls: r =0.885, p<0.001	Canatan et al. 2012
(a) Brazil (b) Community (c) Cohort study	Pregnant women (n = 42)	Not reported	(a) First trimester: 57.8 \pm 77.3 mg/dL (b) Third trimester: 93.1 \pm 175.7 mg/dL (c) Post-	(a) First trimester: 106.4 \pm 27.5 mg/dL (b) Third trimester: 90.0 \pm 40.5 mg/dL (c) Post-partum:	(a) significant positive correlation between serum Fe levels in the first trimester and	Costa et al. 2017

			partum: 42.3 ± 124.3 mg/dL	86.3 ± 26.3 mg/dL	salivary Fe levels in the second trimester (r = 0.99, p = 0.045). (b) no other statistically significant correlation s	
(a) Turkey (b) Hospital (c) Cross-sectional study	(a) healthy control (n = 40) (b) peritoneal dialysis (n = 44) (c) hemodialysis patients (n = 44)	(a) 43.9±8.5 years (b) 45.8 ±13.3 years (c) 48.2±12.3 years	(a) healthy controls: 0.65 ± 0.51 µmol/L (b) peritoneal dialysis: 1.16 ± 1.42 µmol/L (c) before hemodialysis: 0.84 ± 1.00 µmol/L (d) after hemodialysis: 0.57 ± 0.74 µmol/L	(a) healthy controls: 12.96 ± 6.98 µmol/L (b) peritoneal dialysis: 11.29 ± 3.62 µmol/L (c) before hemodialysis: 11.99 ± 7.05 µmol/L (d) after hemodialysis: 13.75 ± 11.01 µmol/L	(a) healthy controls: not reported (b) peritoneal dialysis: not reported (c) before hemodialysis: not reported (d) after hemodialysis: is: r = 0.40, p = 0.007	Alpdemir et al. 2018
(a) Iran (b) Hospital (c) Case-control study	(a) patients with OLP (n = 40) - non-erosive group (n = 22) - erosive group (n = 18) (b) age- and sex-matched controls (n = 40)	(a) 46.6±11.85 years (b) 46.06±12.1 3 years	(a) patients with OLP: 0.16 ± 0.24 mmol/L - non- erosive group: 0.13 ± 0.23 mmol/L - erosive group: 0.19 ± 0.25 mmol/L (b) age-	Not done	Not done	Rezazadeh et al. 2019

			and sex-matched controls: 0.11 ± 0.10 mmol/L			
(a) Italy (b) Hospital (c) Cross-sectional study	(a) healthy control group (n = 20) (b) untreated periodontitis group (n = 24) (c) treated periodontitis group (n = 22)	(a) 44.3±10.8 years (b) 55.4 ± 13.8 years (c) 53.1 ± 14.6 years	(a) healthy control group: 9.74 ± 6.57 µg/L (b) untreated periodontitis group: 12.56 ± 13.88 µg/L (c) treated periodontitis group: 26.66 ± 27.53 µg/L	Not done	Not done	Romano et al. 2020

1343 SD, standard deviation, IDA, iron deficiency anemia; OLP, oral lichen planus
1344

1345 **Table 4.** Summary of studies with salivary vitamin A and results

(a) Country (b) Settings (c) Design	Study participants with sample size	Age of the participants	Salivary levels of vitamin A (Mean \pm SD)	Serum levels of vitamin A (Mean \pm SD)	Correlation coefficients between serum and salivary levels of vitamin A	Reference
(a) United Kingdom (b) Hospital (c) Cross- sectional study	Healthy participants (n = 14)	Not reported	(a) RBP at resting stage: 2100.00 \pm 2150.00 ng/m L (b) RBP at stimulated stage: 1600.00 \pm 1700.00 ng/m L	(a) Serum retinol: 2.08 \pm 0.39 μ mol/L (b) Serum RBP: Not reported	(a) Salivary RBP concentration vs. serum RBP concentration : $r^2 = 0.09$, $p > 0.05$ (b) Salivary RBP vs. serum retinol concentration : $r^2 = 0.04$, $p = 0.05$	Blakeley et al. 2020
(a) Iran (b) Dental college (c) Cross- sectional study	(a) patients with OLP (n = 28) - non- erosive group (n = 17) - erosive group (n = 11) (b) healthy controls (n = 30)	44.96 \pm 10.32 years	(a) Vitamin A in patients with OLP: 10.45 ng/mL - non-erosive group: 10.81 \pm 0.95 ng/mL - erosive group: 9.91 \pm 0.68 ng/mL (b) Vitamin A in healthy controls: 12.97 ng/mL	Not done	Not done	Rezazadeh et al. 2023

1346 SD, standard deviation; RBP, retinol binding protein; OLP, oral lichen planus

1347

1348 **Table 5.** Summary of studies with salivary vitamin D and results

(a) Country (b) Settings (c) Design	Study participants with sample size	Age of the participants	Salivary levels of vitamin D (Mean \pm SD)	Serum levels of vitamin D (Mean \pm SD)	Correlation coefficient between serum and salivary levels of vitamin D	Reference
(a) Iran (b) University hospital (c) Cross-sectional study	(a) patients with RAS (n = 26) (b) healthy individuals (n = 26)	(a) 38.80 \pm 12.02 years (b) 40.80 \pm 11.60 years	(a) RAS Patients: 17.36 \pm 8.01 ng/dL (b) healthy individuals: 20.79 \pm 6.31 ng/dL	(a) RAS Patients: 33.07 \pm 12.41 ng/dL (b) healthy Individuals: 50.89 \pm 9.30 ng/dL	r = 0.56 (p < 0.001)	Bahramian et al. 2018
(a) Italy (b) Clinic/hospital (c) Cross-sectional study	(a) patients with PD (n = 21) (b) healthy controls (n = 21)	(a) 56.9 \pm 5.4 years (b) 54.3 \pm 5.0 years	(a) PD: 3.7 \pm 2.4 ng/mL (b) healthy controls: 4.6 \pm 3.6 ng/mL	Not done	Not done	Costantini et al. 2020
(a) Poland (b) Schools (c) Cross-sectional study	(a) pre-pubertal children (n = 100) (b) pubertal children (n = 76)	6 to 13 years	(a) pre-pubertal children: 33.03 \pm 18.36 ng/mL (b) pubertal children: 23.82 \pm 14.72 ng/mL (c) overall: 29.05 \pm 17.45 ng/mL	Not done	Not done	Pruszkowska-Przybylska et al. 2020
(a) Brazil (b) Schools (c) Cross-sectional study	(a) below %BF cutoff (n = 172) (b)	15.66 \pm 0.9 years	(a) below %BF cutoff (n = 111) (b) 25-	Not done	Not done	Araujo et al. 2020

	above %BF cutoff (n = 67)		Hydroxyvitamin-D2: 1.67 ± 0.71 ng/mL - 25-Hydroxyvitamin-D3: 4.08 ± 3.15 ng/mL (b) above %BF cutoff (n = 138) - 25-Hydroxyvitamin-D2: 1.74 ± 0.58 ng/mL - 25-Hydroxyvitamin-D3: 4.00 ± 2.56 ng/mL			
(a) United Kingdom (b) Hospital (c) Cross-sectional study	Healthy participants (n = 14)	Not reported	(a) Resting salivary DBP concentration: 65.0 ± 55.6 ng/mL (b) Stimulated salivary DBP concentration: 55.0 ± 51.9 ng/mL (c) Resting salivary DBP output: 40 ± 25.9 ng/min (d) Stimulated DBP output: 80 ± 44.5 ng/min	(a) Serum 25-OH-D: 40 ± 22 nmol/L (b) Serum DBP: Not reported	(a) Salivary DBP concentration vs. serum DBP concentration: $r^2 = 0.33$ (p<0.05) (b) Salivary DBP output vs. serum DBP concentration: $r^2 = 0.45$ (p<0.01) (c) Salivary DBP concentration vs. Serum 25-OH-D concentration: $r^2 = 0.11$ (p>0.05)	Blakeley et al. 2020

					(d) Salivary DBP output vs. Serum 25-OH-D concentration: $r^2 = 0.15$ ($p > 0.05$)	
(a) Iran (b) University hospital (c) Case-control study	(a) OLP (n = 64), (b) age- and sex-matched healthy controls (n = 45)	Not reported	Unstimulated saliva 25(OH)D concentration (ng/mL): (a) Healthy controls: 0.62 ± 0.07 (b) OLP patients: 0.45 ± 0.05 Stimulated saliva 25(OH)D concentration (ng/mL): (a) Healthy controls: 0.63 ± 0.07 (b) OLP patients: 0.43 ± 0.05 Unstimulated saliva 25(OH)D output (ng/min): (a) Healthy controls: 0.43 ± 0.06 (b) OLP patients: 0.21 ± 0.04 Stimulated saliva	(a) Healthy controls: 36.69 ± 3.79 ng/mL (b) OLP patients: 36.18 ± 3.18 ng/mL	(a) Serum 25(OH)D vs. unstimulated saliva 25(OH)D: $r = 0.148$ ($p = 0.152$) (b) Serum 25(OH)D vs. stimulated saliva 25(OH)D: $r = 0.014$ ($p = 0.895$) (c) Serum 25(OH)D vs. unstimulated saliva flow rate: $r = 0.013$ ($p = 0.911$) (d) Serum 25(OH)D vs. stimulated saliva flow rate: $r = 0.009$ ($p = 0.935$)	Gholizadeh et al. 2020

			25(OH)D output (ng/min): (a) Healthy controls: 0.60 ± 0.11 (b) OLP patients: 0.25 ± 0.04			
(a) United Kingdom (b) Schools and clinics (c) Cross-sectional study	(a) participants with normal BMI (n = 59) (b) participants with obesity (n = 53)	(a) 13.63 ± 2.36 years (b) 14.60 ± 2.05 years	(a) participants with normal BMI: 7.64 ± 3.65 ng/mL (b) participants with obesity: 6.29 ± 5.12 ng/mL	Not done	Not done	Usman et al. 2021
(a) India (b) Dental college (c) Cross-sectional study	(a) OL (n = 15) (b) OSMF (n = 15) (c) OSCC (n = 15) (d) healthy controls (n = 15)	(a) OL: 46.67 ± 18.63 years (b) OSMF: 40.13 ± 11.02 years (c) OSCC: 53.33 ± 8.76 years (d) healthy controls: 42.13 ± 16.90 years (e) overall: 45.57 ± 14.94 years	(a) OL: 31.39 ± 1.72 ng/mL (b) OSMF: 22.37 ± 1.31 ng/mL (c) OSCC: 24.06 ± 1.92 ng/mL (d) healthy controls: 33.61 ± 2.25 ng/mL	(a) OL: 24.19 ± 2.04 ng/mL (b) OSMF: 20.12 ± 1.85 ng/mL (c) OSCC: 18.15 ± 1.71 ng/mL (d) healthy controls: 36.29 ± 3.12 ng/mL	r = 0.737 (p < 0.001)	Samanta et al. 2023
(a) Iran (b) Dental college	(a) patients with OLP	44.96 ± 10.32 years	(a) patients with OLP: 8.96 ± 6.62	Not done	Not done	Rezazadeh et al. 2023

(c) Cross-sectional study	(n = 28) - non-erosive group (n = 17) - erosive group (n = 11) (b) healthy controls (n = 30)		ng/mL - non-erosive group: 8.88 ± 6.98 ng/mL - erosive group: 8.95 ± 6.01 ng/mL (b) healthy controls: 14.22 ng/mL			
---------------------------	---	--	--	--	--	--

1349 SD, standard deviation; RAS, Recurrent Aphthous Stomatitis; PD, periodontitis; %BF, body fat

1350 percentage; DBP, vitamin D binding protein; BMI, body mass index; OL, oral leukoplakia; OSMF,

1351 oral submucous fibrosis; OSCC, oral squamous cell carcinoma; OLP, oral lichen planus.

1352

1353 **Table 6.** Summary of studies with salivary vitamin B12 and results

(a) Country (b) Settings (c) Design	Study participants with sample size	Age of the participants	Salivary levels of vitamin B12 (Mean \pm SD)	Serum levels of vitamin B12 (Mean \pm SD)	Correlation coefficients between serum and salivary levels of vitamin B12	Reference
(a) Turkey (b) Hospital (c) Cross-sectional study	(a) healthy control (n = 40) (b) peritoneal dialysis (n = 44) (c) hemodialysis patients (n = 44)	(a) 43.9 \pm 8.5 years (b) 45.8 \pm 13.3 years (c) 48.2 \pm 12.3 years	(a) healthy controls: 27500.00 \pm 52900.00 pg/mL (b) peritoneal dialysis: 10800.00 \pm 7570.00 pg/mL (c) before hemodialysis: 34900.00 \pm 22200.00 pg/mL (d) after hemodialysis: 61100.00 \pm 58000.00 pg/mL	(a) healthy controls: 247.0 \pm 120.0 pg/mL (b) peritoneal dialysis: 500.0 \pm 303.0 pg/mL (c) before hemodialysis: 368.0 \pm 58.6 pg/mL (d) after hemodialysis: 286.0 \pm 96.6 pg/mL	(a) healthy controls: not reported (b) peritoneal dialysis: not reported (c) before hemodialysis: not reported (d) after hemodialysis: not reported (e) all groups: r = 0.16, p = 0.035	Alpdemir et al. 2018
(a) Iraq (b) Hospital (c) Cross-sectional study	(a) IDA with RAS (n = 25) (b) IDA without RAS (n = 25) (c) healthy controls (n = 25)	38.3 \pm 13.3 years	(a) IDA with RAS: 100.0 \pm 14.8 pg/mL (b) IDA without RAS: 120.0 \pm 111.1 pg/mL (c) healthy controls:	(a) IDA with RAS: 111.0 \pm 15.4 pg/mL (b) IDA without RAS: 145.0 \pm 57.2 pg/mL (c) healthy controls:	Not done	Al-hamdani et al. 2023

			330.0 ± 30.0 pg/mL	396.0 ± 18.2 pg/mL		
(a) United Kingdom (b) Hospital (c) Cross-sectional study	Healthy participants (n = 14)	Not reported	(a) Resting: 48.00 ± 16.30 pg/mL (b) Stimulated: 30.00 ± 17.78 pg/mL	(a) Serum total vitamin B12: 196 ± 92 pmol/L (b) Serum haptocorrin : not reported	(a) Salivary vs. serum haptocorrin concentration: $r^2 = 0.02$, $p > 0.05$ (b) Salivary haptocorrin vs. serum total vitamin B12 concentration: $r^2 = 0.08$, $p = 0.05$	Blakeley et al. 2020
(a) Iran (b) Dental college (c) Cross-sectional study	(a) patients with OLP (n = 28) - non-erosive group (n = 17) - erosive group (n = 11) (b) healthy controls (n = 30)	44.96 ± 10.32 years	(a) patients with OLP: 910000 pg/mL - non-erosive group: 940000.00 ± 760000.00 pg/mL - erosive group: 870000.00 ± 510000.00 pg/mL (b) healthy controls: 980000.00 pg/mL	Not done	Not done	Rezazadeh et al. 2023

1354 SD, standard deviation; IDA, iron deficiency anemia; RAS, recurring aphthous ulcers; OLP, oral

1355 lichen planus.

1356

1357 **Table 7.** Summary of studies with salivary CRP and results

(a) Country (b) Settings (c) Design	Study participants with sample size	Age of the participants	Salivary levels of CRP (Mean \pm SD)	Serum levels of CRP (Mean \pm SD)	Corr elati on coeff icien ts betw een seru m and saliv ary level s of CRP	Reference
(a) South Africa (b) School (c) Cross - sectional	(a) Children with normal weight children (n = 93) (b) Children with overweight (n = 24) (c) Children with obesity (n = 53)	(a) 9.71 \pm 1.84 years (b) 9.25 \pm 1.67 years (c) 9.55 \pm 1.63 years	(a) 0.00001 \pm 0.000001 $\mu\text{g/mL}$ (b) 0.00001 \pm 0.000001 $\mu\text{g/mL}$ (c) 0.00001 \pm 0.000001 $\mu\text{g/mL}$	Not done	Not done	Naidoo et al. 2012
(a) USA (b) Hospital (c) Cross - sectional	(a) Acute myocardial infraction (n = 92) (b) Controls (n = 111)	(a) 54.2 \pm 11.9 years (b) 48.6 \pm 8.9 years	(a) 0.003 \pm 0.006 $\mu\text{g/mL}$ (b) 0.0001 \pm 0.001 $\mu\text{g/mL}$	(a) 0.005 \pm 0.005 $\mu\text{g/mL}$ (b) 0.001 \pm 0.001 $\mu\text{g/mL}$	Not done	Ebersole et al. 2017

(a) USA (b) Community (c) Cross-sectional	(a) Children with normal weight (n = 40) (b) Children with overweight or obesity (n = 36)	(a) 8.38 ± 0.23 years (b) 8.49 ± 0.23 years	(a) 0.00004 µg/mL (b) 0.0002 µg/mL	Not done	Not done	Selvaraju et al. 2019
(a) Sweden (b) Community (c) Cross-sectional	Healthy participants (n = 107)	Median age: 57, Age range: 45–69 years	(a) Morning level: 0.06 ± 0.22 µg/ml (b) Evening level: 0.01 ± 0.02 µg/ml	2.4 ± 4.68 µg/mL	a) Morning salivary CRP vs. serum CRP : no significant correlation (b) Evening salivary CRP vs. serum CRP : rho = 0.27 (p<0.01)	Wetterö et al. 2020

(a) Spain (b) School (c) Observational study (Cohort study)	Healthy children (n = 129)	11 ± 0.74 years	0.002 ± 0.01 µg/ml	1.20 ± 3.12 ug/mL	Overall: rho = 0.77 (p < 0.001) Boys: rho = 0.81 (p < 0.001) Girls: rho = 0.78 (p < 0.001)	Tvarijonavi ciute et al. 2020
(a) Nigeria (b) Hospital (c) Case-control	(a) Patients with diabetes (n = 39) (b) Controls (n = 36)	(a) 57.0 ± 12.0 years (b) 34.5 ± 8.6 years	(a) 0.05 ± 0.04 µg/ml (b) 0.02 ± 0.02 µg/ml	Not done	Not done	Agho et al. 2021
(a) Kuwait (b) School (c) Longitudinal cohort study	(a) Children with normal weight (n = 232) (b) Children with overweight or obesity (n = 121)	(a) 17.1 years (b) 17.0 years	Visit 1 (n = 815): 0.000002 ± 0.000001 µg/mL Visit 2 (n = 42): 0.000003 ± 0.000001 µg/mL Visit 3 (n = 352): 0.000003 ± 0.000001 µg/mL	Visit 1: Not done Visit 2: Not done Visit 3 (n = 352): 0.000001 ± 0.000001 µg/mL	Visit 1: NA Visit 2: NA Visit 3: r = 0.7 (p < 0.0001)	Alqaderi et al. 2022

(a) Germ any (b) Clini c (c) Expl orativ e pilot study	(a) Children with normal weight (n = 19) (b) Children with overweight or obesity (n = 19)	(a) 9.7 ± 2.5 years (b) 10.1 ± 1.9 years	(a) 0.0002 ± 0.001 µg/mL (b) 0.001 ± 0.001 µg/mL	Not done	Not done	Bizjak et al. 2022
(a) Indon esia (b) Hosp ital (c) Cross - section al	(a) Patients with diabetes (n = 10) (b) Control (n = 13)	Not reported	(a) 0.242 ± 0.094 µg/ml (b) 0.248 ± 0.091 µg/ml	Not done	Not done	Bachtiar et al. 2023

1358 SD, standard deviation; CRP, C-reactive protein.

1359

1360 **Figure Legend**


1361 **Figure 1.** PRISMA diagram showing the study selection process in this review





1362 **Figure 2.** Forest plot of pooled correlation coefficients between serum and salivary biomarkers


1363 **Figure 3.** Methodological Challenges and Considerations for the Analysis of Saliva Samples in
1364 Nutrition and Biomedical Research.

1365 **Figure 4.** Future applications of saliva-based diagnostics for the assessment of nutritional status
1366 and inflammatory conditions in different settings

Journal Pre-proof







Future Applications of Salivary Diagnostics for Nutrition and Inflammation Assessment

